Сравнительный анализ рекомендаций по менеджменту пациентов с АНЦА-ассоциированными васкулитами и поражением почек

Authors: I.Yu. Golovach, Ye.D. Yehudina

Source: Počki, Vol 9, Iss 2, Pp 105-116 (2020)
KIDNEYS; Том 9, № 2 (2020); 105-116
Почки-Počki; Том 9, № 2 (2020); 105-116
Нирки-Počki; Том 9, № 2 (2020); 105-116

Subject Terms: antineutrophil cytoplasmic antibodies, kidneys, антинейтрофільні цитоплазматичні антитіла, васкуліти, нирки, нефрит, менеджмент, рекомендації, nephritis, антинейтрофильные цитоплазматические антитела, васкулиты, почки, рекомендации, vasculitis, management, guidelines, RC870-923, Diseases of the genitourinary system. Urology, 3. Good health

File Description: application/pdf

Access URL: https://doaj.org/article/bebb71307d314b5fb387f7e1c0fbf2df
http://kidneys.zaslavsky.com.ua/article/view/203410
http://kidneys.zaslavsky.com.ua/article/download/203410/205615
http://kidneys.zaslavsky.com.ua/article/view/203410

Гастроинтестинальные проявления системных васкулитов: спектр клинических симптомов, диагностика и лечение

Authors: I.Yu. Golovach, Ye.D. Yehudina

Source: Gastroenterologìa, Vol 53, Iss 4, Pp 291-304 (2019)
GASTROENTEROLOGY; Том 53, № 4 (2019); 291-304
Гастроэнтерология-Gastroenterologìa; Том 53, № 4 (2019); 291-304
Гастроентерологія-Gastroenterologìa; Том 53, № 4 (2019); 291-304

Subject Terms: системний васкуліт, шлунково-кишковий тракт, діагностика, лікування, антинейтрофільні цитоплазматичні антитіла, хвороба Бехчета, вузликовий поліартеріїт, treatment, diagnosis, systemic vasculitis, gastrointestinal tract, antineutrophil cytoplasmic antibodies, Behcet's di­sease, polyarteritis nodosa, RC799-869, Diseases of the digestive system. Gastroenterology, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, системный васкулит, желудочно-кишечный тракт, диагностика, лечение, антинейтрофильные цитоплазматические антитела, болезнь Бехчета, узелковый полиартериит, behcet's di­sease

File Description: application/pdf

Access URL: http://gastro.zaslavsky.com.ua/article/download/182405/187580
https://doaj.org/article/2649c0b0fb444941878f5c1d9eb3cb96
http://gastro.zaslavsky.com.ua/article/view/182405
http://gastro.zaslavsky.com.ua/article/download/182405/187580
http://gastro.zaslavsky.com.ua/article/view/182405

New ACR/EULAR 2022 classification criteria for ANCA-associated vasculitis ; Новые классификационные критерии АНЦА-ассоциированных системных васкулитов ACR/EULAR 2022

Authors: T. V. Beketova, Т. В. Бекетова

Source: Rheumatology Science and Practice; Vol 61, No 5 (2023); 531-536 ; Научно-практическая ревматология; Vol 61, No 5 (2023); 531-536 ; 1995-4492 ; 1995-4484

Subject Terms: классификационные критерии, antineutrophil cytoplasmic antibodies, granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, classification criteria, антинейтрофильные цитоплазматические антитела, гранулематоз с полиангиитом, микроскопический полиангиит, эозинофильный гранулематоз с полиангиитом

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3347/2312; Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1): 1-11. doi:10.1002/art.37715; Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. 1990;33(8):1101-1107. doi:10.1002/art.1780330807; Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg – Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094-1100. doi:10.1002/art.1780330806; Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222-227. doi:10.1136/ard.2006.054593; Pierrot-Deseilligny Despujol C, Pouchot J, Pagnoux C, Coste J, Guillevin L. Predictors at diagnosis of a first Wegener’s granulomatosis relapse after obtaining complete remission. Rheumatology (Oxford). 2010;49(11):2181-2190. doi:10.1093/rheumatology/keq244; Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37(2):187-192. doi:10.1002/art.1780370206; Schönermarck U, Lamprecht P, Csernok E, Gross WL. Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. Rheumatology (Oxford). 2001;40(2):178-184. doi:10.1093/rheumatology/40.2.178; Unizony S, Villarreal M, Miloslavsky EM, Lu N, Merkel PA, Spiera R, et al.; RAVE-ITN Research Group. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. 2016;75(6):1166-1169. doi:10.1136/annrheumdis-2015-208073; Syed R, Rehman A, Valecha G, El-Sayegh S. Pauci-immune crescentic glomerulonephritis: An ANCA-associated vasculitis. Biomed Res Int. 2015;2015:402826. doi:10.1155/2015/402826; Бекетова ТВ, Фролова НФ, Столяревич ЕС, Волков МЮ, Котенко ОН, Александрова ЕН. Проблемы диагностики и лечения АНЦА-ассоциированных системных васкулитов: в фокусе АНЦА-негативный pauci-иммунный гломерулонефрит. Научно-практическая ревматология. 2016;54(5):543-552. doi:10.14412/1995-4484-2016-543-552; Eisenberger U, Fakhouri F, Vanhille P, Beaufils H, Mahr A, Guillevin L, et al. ANCA-negative pauci-immune renal vasculitis: Histology and outcome. Nephrol Dial Transplant. 2005;20(7):1392-1399. doi:10.1093/ndt/gfh830; Finkielman JD, Lee AS, Hummel AM, Viss MA, Jacob GL, Homburger HA, et al.; WGET Research Group. ANCA are detectable in nearly all patients with active severe Wegener’s granulomatosis. Am J Med. 2007;120(7):643.e9-643.e14. doi:10.1016/j.amjmed.2006.08.016; Chen LYC, Mattman A, Seidman MA, Carruthers MN. IgG4-related disease: What a hematologist needs to know. Haematologica. 2019;104(3):444-455. doi:10.3324/haematol.2018.205526; Seeliger B, Sznajd J, Robson JC, Judge A, Craven A, Grayson PC, et al. Are the 1990 American College of Rheumatology vasculitis classification criteria still valid? Rheumatology (Oxford). 2017;56(7):1154-1161. doi:10.1093/rheumatology/kex075; Watts RA, Suppiah R, Merkel PA, Luqmani R. Systemic vasculitis – Is it time to reclassify? Rheumatology (Oxford). 2011;50(4):643-645. doi:10.1093/rheumatology/keq229; Basu N, Watts R, Bajema I, Baslund B, Bley T, Boers M, et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis. 2010;69(10):1744-1750. doi:10.1136/ard.2009.119032; Robson JC, Grayson PC, Ponte C, Suppiah R, Craven A, Judge A, et al.; DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Arthritis Rheumatol. 2022;74(3):393-399. doi:10.1002/art.41986; Suppiah R, Robson JC, Grayson PC, Ponte C, Craven A, Khalid S, et al.; DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Arthritis Rheumatol. 2022;74(3):400-406. doi:10.1002/art.41983; Grayson PC, Ponte C, Suppiah R, Robson JC, Craven A, Judge A, et al.; DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Arthritis Rheumatol. 2022;74(3):386-392. doi:10.1002/art.41982; Бекетова ТВ. Гранулематоз с полиангиитом, патогенетически связанный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения. Научно-практическая ревматология. 2012;50(6):19-28. doi:10.14412/1995-4484-2012-1288

Availability: https://rsp.mediar-press.net/rsp/article/view/3347
https://doi.org/10.47360/1995-4484-2023-531-536

Late-onset neutropenia induced by anti-B cell therapy with rituximab in patients with ANCA-associated systemic vasculitis ; Поздняя отсроченная нейтропения, индуцированная анти-В-клеточной терапией ритуксимабом, у пациентов с АНЦА-ассоциированными системными васкулитами

Authors: T. V. Beketova, I. Yu. Popov, V. V. Babak, Т. В. Бекетова, И. Ю. Попов, В. В. Бабак

Source: Modern Rheumatology Journal; Том 16, № 3 (2022); 37-41 ; Современная ревматология; Том 16, № 3 (2022); 37-41 ; 2310-158X ; 1996-7012

Subject Terms: васкулит, rituximab, B cells, antineutrophil cytoplasmic antibodies, vasculitis, ритуксимаб, В-клетки, антинейтрофильные цитоплазматические антитела

File Description: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1295/1245; https://mrj.ima-press.net/mrj/article/view/1295/1246; Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Sep;75(9):1583-94. doi:10.1136/annrheumdis-2016-209133. Epub 2016 Jun 23.; Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? Int J Infect Dis. 2011 Jan;15(1):e2-16. doi:10.1016/j.ijid.2010.03.025. Epub 2010 Nov 11.; Насонов ЕЛ, Бекетова ТВ, Ананьева ЛП и др. Перспективы анти-В-клеточнои терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57(Прил. 1):3-40.; Grant C, Wilson WH, Dunleavy K. Neutropenia associated with rituximab therapy. Curr Opin Hematol. 2011 Jan;18(1):49-54. doi:10.1097/MOH.0b013e3283414edf.; Tesfa D, Ajeganova S, Hägglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic disease: association with B-lymphocyte depletion and infections. Arthritis Rheum. 2011 Aug;63(8):2209-14. doi:10.1002/art.30427.; Salmon JH, Cacoub P, Combe B, et al. Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the Auto- Immunity and Rituximab registry. RMD Open. 2015 Jun 30;1(1):e000034. doi:10.1136/rmdopen-2014-000034. eCollection 2015.; Leavitt RY, Fauci A, Block D, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. 1990 Aug;33(8): 1101-7. doi:10.1002/art.1780330807.; Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 Jan;65(1):1-11. doi:10.1002/art.37715.; Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990 Aug;33(8): 1094-100. doi:10.1002/art.1780330806.; Zonozi R, Laliberte K, Rosenthal J, et al. Late-Onset Neutropenia in patients undergoing rituximab-induced continuous B-cell depletion for autoimmune disease: data from a 738-patient cohort and approach to management. Rheumatology. 2019;58 (Suppl. 2):364. doi:10.1093/rheumatology/kez063.088; Hessels AC, Rutgers A, Sanders JSF, Stegeman CA. Thiopurine methyltransferase genotype and activity cannot predict outcomes of azathioprine maintenance therapy for antineutrophil cytoplasmic antibody associated vasculitis: A retrospective cohort study. PLoS One. 2018 Apr 9;13(4):e0195524. doi:10.1371/journal.pone.0195524. eCollection 2018.; Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/ Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis Rheumatol. 2021 Aug;73(8):1366-83. doi:10.1002/art.41773. Epub 2021 Jul 8.; Roumier M, Paule R, Vallеe A, et al. Tocilizumab for Severe Worsening COVID-19 Pneumonia: A Propensity Score Analysis. J Clin Immunol. 2021 Feb;41(2):303-14. doi:10.1007/s10875-020-00911-6. Epub 2020 Nov 14.; Chaiwatanatorn K, Lee N, Grigg A, et al. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol. 2003 Jun; 121(6):913-8. doi:10.1046/j.1365-2141.2003. 04385.x.; Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med. 2003 Jun 26;348(26): 2691-4; discussion 2691-4. doi:10.1056/NEJM200306263482620.; Papadaki T, Stamatopoulos K, Stavroyianni N, et al. Evidence for T-large granular lymphocyte-mediated neutropenia in rituximab-treated lymphoma patients: report of two cases. Leuk Res. 2002 Jun;26(6):597-600. doi:10.1016/s0145-2126(01)00183-7.; Terrier B, Ittah M, Tourneur L, et al. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF- induced B-cell recovery. Haematologica. 2007 Feb;92(2): e20-3. doi:10.3324/haematol.11031.; Cairoli R, Grillo G, Tedeschi A, et al. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologica. 2004 Mar; 89(3):361-3.; Dunleavy K, Hakim F, Kim HK, et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor and granulocyte homeostasis. Blood. 2005 Aug 1;106(3):795-802. doi:10.1182/blood-2004-08-3198. Epub 2005 Feb 17.; Fukuno K, Tsurumi H, Ando N, et al. Late-onset neutropenia in patients treated with rituximab for non-Hodgkin’s lymphoma. Int J Hematol. 2006 Oct;84(3):242-7. doi:10.1532/IJH97.05105.; Tesfa D, Gelius T, Sander B, et al. Lateonset neutropenia associated with rituximab therapy; evidence for maturation arrest at (pro-) myleocyte stage of granulopoesis. Med Oncol. 2008;25(4):374-9. doi:10.1007/s12032-008-9049-z. Epub 2008 Feb 16.; Carlsson G, Andersson M, Putsep K, et al. Kostmann syndrome or infantile genetic agranulocytosis, part one: celebrating 50 years of clinical and basic research on severe congenital neutropenia. Acta Paediatr. 2006 Dec; 95(12):1526-32. doi:10.1080/08035250601087607.; Carlsson G, Melin M, Dahl M, et al. Kostmann syndrome or infantile genetic agranulocytosis, part two: understanding the underlying genetic defects in severe congenital neutropenia. Acta Paediatr. 2007 Jun; 96(6):813-9. doi:10.1111/j.1651-2227.2007.00274.x.

Availability: https://mrj.ima-press.net/mrj/article/view/1295
https://doi.org/10.14412/1996-7012-2022-3-37-41

Роль оториноларинголога в диагностике гранулематоза ; Role of otorinolaryngologist in diagnostics of granulematosis

Authors: Vedernikova, E. E., Egorushkina, A. V., Davydov, R. S., Abdulkerimov, Z. Kh., Ведерникова, Е. Э., Егорушкина, А. В., Давыдов, Р. С., Абдулкеримов, З. Х.

Source: Сборник статей

Subject Terms: WEGENER'S GRANULOMATOSIS, CLINICAL MANIFESTATIONS, ANTINEUTROPHILIC CYTOPLASMIC ANTIBODIES, ГРАНУЛЕМАТОЗ ВЕГЕНЕРА, КЛИНИЧЕСКИЕ ПРОЯВЛЕНИЯ, АНТИНЕЙТРОФИЛЬНЫЕ ЦИТОПЛАЗМАТИЧЕСКИЕ АНТИТЕЛА

File Description: application/pdf

Relation: Актуальные вопросы современной медицинской науки и здравоохранения: Материалы VI Международной научно-практической конференции молодых учёных и студентов, посвященной году науки и технологий, (Екатеринбург, 8-9 апреля 2021): в 3-х т.; http://elib.usma.ru/handle/usma/5406

Availability: http://elib.usma.ru/handle/usma/5406

Review of guideline for the management of ANCA-associated vasculitis, presented in 2021 by the American College of Rheumatology/Vasculitis Foundation ; Обзор рекомендаций по лечению АНЦА-ассоциированных системных васкулитов, представленных в 2021 г. Американской коллегией ревматологов и Фондом васкулитов

Authors: T. V. Beketova, I. Yu. Popov, V. V. Babak, Т. В. Бекетова, И. Ю. Попов, В. В. Бабак

Source: Rheumatology Science and Practice; Vol 59, No 6 (2021); 684-692 ; Научно-практическая ревматология; Vol 59, No 6 (2021); 684-692 ; 1995-4492 ; 1995-4484

Subject Terms: ритуксимаб, antineutrophil cytoplasmic antibodies, granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, rituximab, антинейтрофильные цитоплазматические антитела, гранулематоз с полиангиитом, микроскопический полиангиит, эозинофильный гранулематоз с полиангиитом

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3102/2146; Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;73(8):1366-1383. doi:10.1002/art.41773; Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Toumelin PL; French Vasculitis Study Group (FVSG). The Five-Factor Score revisited: Assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011;90(1):19-27. doi:10.1097/MD.0b013e318205a4c6; Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al.; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232. doi:10.1056/NEJMoa0909905; Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al.; European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211-220. doi:10.1056/NEJMoa0909169; Kahn JE, Grandpeix-Guyodo C, Marroun I, Catherinot E, Mellot F, Roufosse F, et al. Sustained response to mepolizumab in refractory Churg - Strauss syndrome. J Allergy Clin Immunol. 2010;125(1):267-270. doi:10.1016/j.jaci.2009.10.014; Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921-1932. doi:10.1056/NEJMoa1702079; Menditto VG, Rossetti G, Olivari D, Angeletti A, Rocchi M, Gabrielli A, et al. Rituximab for eosinophilic granulomatosis with polyangiitis: A systematic review of observational studies. Rheumatol. 2021;60:1640-1650. doi:10.1093/rheumatology/keab046; Akiyama M, Kaneko Y, Takeuchi T. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: A systematic literature review. Autoimmun Rev. 2021;20:102737. doi:10.1016/j.autrev.2020.102737; Walsh M, Merkel PA, Peh CA, Szpirt WM, Putehal X, Fujimoto S, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382:622-631. doi:10.1056/NEJMoa1803537; Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18:2180-2188. doi:10.1681/ASN.2007010090; Walsh M, Casian A, Flossmann O, Westman K, Hoglund P, Pusey C, et al.; European Vasculitis Study Group (EUVAS). Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 2013;84(2):397-402. doi:10.1038/ki.2013.131; Teixeira V, Mohammad AJ, Jones RB, Smith R, Jayne D. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open. 2019;5(1):e000905. doi:10.1136/rmdopen-2019-000905; Crickx E, Machelart I, Lazaro E, Kahn JE, Cohen-Aubart F, Martin T, et al. Intravenous immunoglobulin as an immunomodulating agent in antineutrophil cytoplasmic antibody-associated vas-culitides: A French nationwide study of ninety-two patients. Arthritis Rheumatol. 2016;68:702-712. doi:10.1002/art.39472; De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:2461-2469. doi:10.1002/art.21142; Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771-1780. doi:10.1056/NEJMoa1404231; Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790-2803. doi:10.1056/NEJMoa0802311; Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled trial. JAMA. 2010;304:2381-2388. doi:10.1001/jama.2010.1658; Puéchal X, Pagnoux C, Baron G, Quémeneur T, Néel A, Agard C, et al. Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg - Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: A randomized, controlled trial. Arthritis Rheumatol. 2017;69:2175-2186. doi:10.1002/art.40205; Metzler C, Miehle N, Manger K, Iking-Konert C, de Groot K, Hellmich B, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford). 2007;46:1087-1091. doi:10.1093/rheumatology/kem029; Kado R, Sanders G, McCune WJ. Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy (review). Curr Opin Rheumatol. 2017;29:228-233. doi:10.1097/BOR.0000000000000377; Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198-1207. doi:10.1056/NEJMoa1403290; Joshi L, Tanna A, McAdoo SP, Medjeral-Thomas N, Taylor SR, Sandhu G, et al. Long-term outcomes of rituximab therapy in ocular granulomatosis with polyangiitis: Impact on localized and nonlocalized disease. Ophthalmology. 2015;122:1262-1268. doi:10.1016/j.ophtha.2015.01.016; Durel CA, Hot A, Trefond L, Aumaitre O, Pugnet G, Samson M, et al. Orbital mass in ANCA-associated vasculitides: Data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients. Rheumatology (Oxford). 2019;58:1565-1573. doi:10.1093/rheumatology/Kez071; Girard C, Charles P, Terrier B, Bussonne G, Cohen P, Pagnoux C, et al. Tracheobronchial stenoses in granulomatosis with polyangiitis (Wegener's): A report on 26 cases. Medicine (Baltimore). 2015;94:e1088. doi:10.1097/MD.0000000000001088; Sagmeister MS, Grigorescu M, Schonermarck U. Kidney transplantation in ANCA-associated vasculitis. J Nephrol. 2019;32:919-926. doi:10.1007/s40620-019-00642-x; Geetha D, Eirin A, True K, Valentina Irazabal M, Specks U, Seo P, et al. Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: A multicenter experience. Transplantation. 2011;91:1370-1375. doi:10.1097/TP.0b013e31821ab9aa; Sachse F, Stoll W. Nasal surgery in patients with systemic disorders. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2010;9:Doc02. doi:10.3205/cto000066; Congdon D, Sherris DA, Specks U, McDonald T. Long-term follow-up of repair of external nasal deformities in patients with Wegener's granulomatosis. Laryngoscope. 2002;112:731-737. doi:10.1097/00005537-200204000-00025; Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis - A meta-analysis. Rheumatology (Oxford). 2012;51(1):100-109. doi:10.1093/rheumatology/ker280; Charles P, Terrier B, Perrodeau E, Cohen P, Faguer S, Huart A, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77:1143-1149. doi:10.1136/annrheumdis-2017-212878

Availability: https://rsp.mediar-press.net/rsp/article/view/3102
https://doi.org/10.47360/1995-4484-2021-684-692

The diagnostic and prognostic value of serological markers of inflammatory bowel diseases (a literature review) ; Диагностическая и прогностическая значимость серологических маркеров воспалительных заболеваний кишечника (обзор литературы)

Authors: Kuznetsova D.А., Lapin S.V., Shchukina O.B.

Source: Almanac of Clinical Medicine; Vol 48, No 6 (2020); 364-374 ; Альманах клинической медицины; Vol 48, No 6 (2020); 364-374 ; 2587-9294 ; 2072-0505

Subject Terms: ulcerative colitis, Crohn's disease, autoantibodies, anti-neutrophil cytoplasmic antibodies, Saccharomyces сerevisiae, goblet cells, glycoprotein 2, CUZD1, язвенный колит, болезнь Крона, аутоантитела, антинейтрофильные цитоплазматические антитела, Saccharomyces cerevisiae, бокаловидные клетки, гликопротеин 2

File Description: application/pdf

Relation: https://almclinmed.ru/jour/article/view/1386/1270; https://almclinmed.ru/jour/article/downloadSuppFile/1386/2171; https://almclinmed.ru/jour/article/view/1386

Availability: https://almclinmed.ru/jour/article/view/1386
https://doi.org/10.18786/2072-0505-2020-48-061

ТРУДНОСТИ ДИАГНОСТИКИ ГРАНУЛЕМАТОЗА С ПОЛИАНГИИТОМ У РЕБЕНКА С СОПУТСТУЮЩИМ АСПЕРГИЛЛЕЗОМ ЛЕГКИХ

Subject Terms: гранулематоз с полиангиитом, antineutrophil cytoplasmic antibodies, granulomatosis with polyangiitis, хроническая болезнь почек, антинейтрофильные цитоплазматические антитела, adolescent, васкулит, aspergillosis pneumonia, ребенок пубертатного возраста, vasculitis, chronic kidney disease, 3. Good health, аспергиллезная пневмония

Трудности и ошибки в диагностике первопричины лихорадки неясного генеза (клинический случай)

Authors: Викторова, И. А., Голошубина, В. В., Гришечкина, И. А., Бунова, С. С.

Subject Terms: медицина, внутренние болезни, ревматология, лихорадка неясного генеза, системные васкулиты, гранулематоз Вегенера, антинейтрофильные цитоплазматические антитела, протеиназа-3, ошибки диагностики

Relation: http://dspace.bsu.edu.ru/handle/123456789/61908

Availability: http://dspace.bsu.edu.ru/handle/123456789/61908

Трудности и ошибки в диагностике первопричины лихорадки неясного генеза (клинический случай)

Subject Terms: системные васкулиты, лихорадка неясного генеза, антинейтрофильные цитоплазматические антитела, ревматология, гранулематоз Вегенера, протеиназа-3, ошибки диагностики, медицина, внутренние болезни

Access URL: https://openrepository.ru/article?id=19255

PERIODONTAL DISEASES AND SYSTEMIC VASCULITIS: A VIEW THROUGH THE PRISM OF INTERDISCIPLINARY STUDIES ; Патология периодонта и системные васкулиты: взгляд сквозь призму междисциплинарных исследований

Authors: T. V. Beketova, E. I. Selifanova, Т. В. Бекетова, Е. И. Селифанова

Source: Rheumatology Science and Practice; Vol 55, No 6 (2017); 685-689 ; Научно-практическая ревматология; Vol 55, No 6 (2017); 685-689 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20176

Subject Terms: антинейтрофильные цитоплазматические антитела, rheumatic diseases, periodontium, periodontal disease, antineutrophil cytoplasmic antibodies, ревматические заболевания, периодонт, периодонтит

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2475/1644; De Pablo P, Chapple IL, Buckley CD, Dietrich T. Periodontitis in systemic rheumatic diseases. Nat Rev Rheumatol. 2009;5(4):218-24. doi:10.1038/nrrheum.2009.28; Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1-11. doi:10.1002/art.37715; Saffi MAL, Furtado MV, Polanczyk CA, et al. Relationship between vascular endothelium and periodontal disease in athero-sclerotic lesions: Review article. World J Cardiol. 2015;7(1):26-30. doi:10.4330/wjc.v7.i1.26; Dietrich T, Jimenez M, Krall Kaye EA, et al. Age-dependent associations between chronic periodontitis/edentulism and risk of coronary heart disease. Circulation. 2008;117(13):1668-74.; Aarabi G, Eberhard J, Reissmann DR, et al. Interaction between periodontal disease and atherosclerotic vascular disease – Fact or fiction? Atherosclerosis. 2015;241(2):555-60. doi:10.1016/j.atherosclerosis.2015.04.819; Nesse W, Dijkstra PU, Abbas F, et al. Increased prevalence of cardiovascular and autoimmune diseases in periodontitis patients: a cross-sectional study. J Periodontol. 2010;81(11):1622-8. doi:10.1902/jop.2010.100058; Mercado FB, Marshall RI, Bartold PM. Inter-relationships between rheumatoid arthritis and periodontal disease. A review. J Clin Periodontol. 2003;30(9):761-72. doi:10.1034/j.1600-051X.2003.00371.x; Brook I. Microbiology and management of periodontal infections. Gen Dent. 2003;51(5):424-8.; Nair S, Faizuddin M, Dharmapalan J. Role of autoimmune responses in periodontal disease. Autoimmun Dis. 2014;2014:596824. doi:10.1155/2014/596824; Sharma CG, Pradeep AR. Anti-neutrophil cytoplasmic autoanti-bodies: a renewed paradigm in periodontal disease pathogenesis? J Periodontol. 2006;77(8):1304-13. doi:10.1902/jop.2006.050308; Takeuchi Y, Yoshie H, Hara K. Expression of interleukin-2 receptor and HLA-DR on lymphocyte subsets of gingival crevicular fluid in patients with periodontitis. J Periodont Res. 1991;26(6):502-10. doi:10.1111/j.1600-0765.1991.tb01802.x; Sugawara M, Yamashita K, Yoshie H, Hara K. Detection of, and anti-collagen antibody produced by, CD5-positive B cells in inflamed gingival tissues. J Periodont Res. 1992;27(5):489-98. doi:10.1111/j.1600-0765.1992.tb01822.x; D'Aiuto F, Graziani F, Tete S, et al. Periodontitis: from local infection to systemic diseases. Int J Immunopathol Pharmacol. 2005;18(3 Suppl):1-11.; Arigbede AO, Babatope BO, Bamidele MK. Periodontitis and systemic diseases: A literature review. J Indian Soc Periodontol. 2012;16(4):487-91. doi:10.4103/0972-124X.106878; Scannapieco FA, Bush RB, Paju S. Periodontal disease as a risk factor for adverse pregnancy outcome: A systematic review. Ann Periodontol. 2003;8:70-8. doi:10.1902/annals.2003.8.1.70; Slade GD, Ghezzi EM, Heiss G, et al. Relationship between periodontal disease and C-reactive protein among adults in the Atherosclerosis Risk in Communities study. Arch Intern Med. 2003;163(10):1172-9. doi:10.1001/archinte.163.10.1172; Loos BG. Systemic markers of inflammation in periodontitis. J Periodontol. 2005;76(11 Suppl):2106-15.; Chukkapalli SS, Rivera-Kweh MF, Velsko IM, et al. Chronic oral infection with major periodontal bacteria Tannerella forsythia modulates systemic atherosclerosis risk factors and inflammatory markers. Pathogen Dis. 2015;73(3). doi:10.1093/femspd/ftv009; Haraszthy V, Zambon J, Trevisan M, et al. Identification of periodontal pathogens in atheromatous plaques. J Periodontol. 2000;71(10):1554-60. doi:10.1902/jop.2000.71.10.1554; Willershausen B, Kasaj A, Willershausen I, et al. Association between chronic dental infection and acute myocardial infarction. J Endodont. 2009;35(5):626-30. doi:10.1016/j.joen.2009.01.012; Mendall MA, Patel P, Ballan L, et al. C-reactive protein and its relation to cardiovascular risk factor: a population based cros-section study. Brit Med J. 1996;312:1061-5. doi:10.1136/bmj.312.7038.1061; Banks M, Flint J, Bacon P, Kitas G. Rheumatoid arthritis is an independent risk factor for ischemic heart disease. Arthritis Rheum. 2000;43 Suppl:385.; Hollan I, Meroni PL, Ahearn JM, et al. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev. 2013;12:1004-15. doi:10.1016/j.autrev.2013.03.013; Ridker PM. Inflammation, infection, and cardiovascular risk: how good is the clinical evidence? Circulation. 1998;97(17):1671-4. doi:10.1161/01.CIR.97.17.1671; Chiu B, Viira E, Tucker W, Fong IW. Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation. 1997;96(7):2144-8.; Wiedermann CJ, Kiechl S, Dunzendorfer S, et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results for the Brunek study. J Am Coll Cardiol. 1999;34:1975-81. doi:10.1016/S0735-1097(99)00448-9; Etemadifar R, Konarizadeh S, Zarei A, et al. Relationship between periodontal status and C-reactive protein and inter-leuckin-6 levels among atherosclerotic patients in Bandar Abbas, Iran in 2014. Electr Phys. 2015;7(1):1010-6.; Glurich I, Grossi S, Albini B, et al. Systemic inflammation in cardiovascular and periodontal disease: comparative study. Clin Diagn Lab Immunol. 2002;9(2):425-32. doi:10.1128/CDLI.9.2.425-432.2002; Pradeep AR, Hadge P, Arjun Raju P, et al. Periodontitis as a risk factor for cerebrovascular accident: a case-control study in the Indian population. J Periodontal Res. 2010;45(2):223-8. doi:10.1111/j.1600-0765.2009.01220.x; Janket SJ, Qvarnströ m M, Meurman JH, et al. Asymptotic dental score and prevalent coronary heart disease. Circulation. 2004;109(9):1095-100. doi:10.1161/01.CIR.0000118497.44961.1E; Vettore MV, Leal M, Leao AT, et al. The Relationship between Periodontitis and Preterm Low Birth weight. J Dent Res. 2008;87:73-8. doi:10.1177/154405910808700113; Goldenberg RL, Culhane JF. Preterm Birth and Periodontal Disease. N Engl J Med. 2006;355:1925-7. doi:10.1056/NEJMe068210; Offenbacher S, Boggess KA, Murtha AP, et al. Progressive periodontal disease and risk of very preterm delivery. Obstet Gynecol. 2006;107:29-36. doi:10.1097/01.AOG.0000190212.87012.96; Pitiphat W, Joshipura K, Gillman MW, et al. Maternal periodonti-tis and adverse pregnancy outcomes. Community Dent Oral Epidemiol. 2008;36:3-11.; Xiong X, Elkind-Hirsch KE, Vastardis S, et al. Periodontal disease is associated with gestational diabetes mellitus: a case-control study. J Periodontol. 2009;80(11):1742-9. doi:10.1902/jop.2009.090250; Negrato CA, Tarzia O, Jovanovic L, Chinellato LE. Periodontal disease and diabetes mellitus. J Appl Oral Sci. 2013;21(1):1-12. doi:10.1590/1678-7757201302106; Dunning T. Periodontal disease – the overlooked diabetes complication. Nephrol Nurs J. 2009;36(5):489-95.; Iacopino AM. Periodontitis and diabetes interrelationships: Role of inflammation. Ann Periodontol. 2001;6:125-37.; Mealey BL, Rose LF. Diabetes mellitus and inflammatory periodontal diseases. Curr Opin Endocrinol Diabetes Obes. 2008;15:135-41. doi:10.1097/MED.0b013e3282f824b7; Rosenquist K. Risk factors in oral and oropharyngeal squamous cell carcinoma: A population-based case-control study in southern Sweden. Swed Dent J. 2005;179:1-66.; Michaud DS, Liu Y, Meyer M, et al. Periodontal disease, tooth loss, and cancer risk in male health professionals: A prospective cohort study. Lancet Oncol. 2008;9:550-8. doi:10.1016/S1470-2045(08)70106-2; Tezal M, Sullivian MA, Hyland A, et al. Chronic periodontitis and the incidence of head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2009;18:2409-12. doi:10.1158/1055-9965.EPI-09-0334; Soory M. Periodontal diseases and rheumatoid arthritis: a coincident model for therapeutic intervention? Curr Drug Metab. 2007;8(8):750-7. doi:10.2174/138920007782798162; Liao F, Li Z, Wang Y, et al. Porphyromonas gingivalis may play an important role in the pathogenesis of periodontitis-associated rheumatoid arthritis. Med Hypoth. 2009;72(6):732-5.; Arkema EV, Karlson EW, Costenbader KH. A prospective study of periodontal disease and risk of rheumatoid arthritis. J Rheumatol. 2010;37(9):1800-4. doi:10.3899/jrheum.091398; Hitchon C, Chandad F, Ferucci E, et al. Antibodies to porphyromonas gingivalis are associated with anticitrullinated protein antibodies in patients with rheumatoid arthritis and their relatives. Rheumatology. 2010;37(6):1105-12. doi:10.3899/jrheum.091323; Bartold P, Marino V, Cantley M, et al. Effect of Porphyromonas gingivalis-induced inflammation on the development of rheumatoid arthritis. J Clin Periodontol. 2010;37(5):405-11.; Lundberg K, Wegner N, Yucel-Lindberg T, Venables PJ. Periodontitis in RA-the citrullinated enolase connection. Nat Rev Rheumatol. 2010;6(12):727-30. doi:10.1038/nrrheum.2010.139; Katz J, Goultschin J, Benoliel R, Brautbar C. Human leukocyte antigen (HLA) DR4. Positive association with rapidly progressing periodontitis. J Periodontol. 1987;58:607-10. doi:10.1902/jop.1987.58.9.607; Bonfil JJ, Dillier FL, Mercier P, et al. A «case control» study on the role of HLA DR4 in severe periodontitis and rapidly progressive periodontitis. Identification of types and subtypes using molecular biology (PcR.SSO). J Clin Periodontol. 1999;26:77-84. doi:10.1034/j.1600-051X.1999.260203.x; Dingle JT, Leeming MRG, Martindale JJ. Effect of Tenidap on cartilage integrity in vitro. Ann Rheum Dis. 1993;52:292-9.; Weyand C, McCarthy T, Goronzy J. Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J Clin Invest. 1995;95:2120-6. doi:10.1172/JCI117900; Marotte H, Farge P, Gaudin P, et al. The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitope and severity of bone destruction. Ann Rheum Dis. 2006;65:905-9. doi:10.1136/ard.2005.036913; Sorensen LK, Havemose-Poulsen A, Sonder SU, et al. Blood cell gene expression profiling in subjects with aggressive periodontitis and chronic arthritis. J Periodontol. 2008;79(3):477-85.; Graves D. Cytokines that promote periodontal tissue destruction. J Periodontol. 2008;79:1585-91. doi:10.1902/jop.2008.080183; McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429-42. doi:10.1038/nri2094; Sorsa T, Tjä derhane L, Konttinen YT, et al. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med. 2006;38(5):306-21. doi:10.1080/07853890600800103; Jeffcoat MK, Geurs NC, Lewis CE Osteoporosis and periodontal bone loss. Clin Calcium. 2003;13(5):577-81.; Mayer Y, Balbir-Gurman A, Machtei EE. Anti-tumor necrosis factor-alpha therapy and periodontal parameters in patients with rheumatoid arthritis. J Periodontol. 2009;80(9):1414-20.; Novo E, Garcia-MacGregor E, Viera N, et al. Periodontitis and anti-neutrophil cytoplasmic antibodies in systemic lupus erythematosus and rheumatoid arthritis: a comparative study. J Periodontol. 1999;70:185-8. doi:10.1902/jop.1999.70.2.185; Rzeszutko W, Konopka T, Kopec W. Anti-neutrophil cytoplasmic antibodies and autoantibodies to human heat shock protein 60; in periodontitis patients. Adv Clin Exp Med. 2006;15(4):599-605.; Gomez-Puerta JA, Bosch X. Anti-neutrophil cytoplasmic antibody pathogenesis in small-vessel vasculitis: an update. Am J Pathol. 2009;175:1790-8. doi:10.2353/ajpath.2009.090533; Kallenberg CG. Pathogenesis of ANCA-associated vasculitis, an update. Clin Rev Allerg Immunol. 2011;41(2):224-31. doi:10.1007/s12016-011-8258-y; Rohini NV, Pradeep AR, Faizuddin M. Antineutrophil cytoplasmic antibodies and adult periodontitis. J Periodont Res. 2000;35(6):374-6. doi:10.1034/j.1600-0765.2000.035006374.x; Stewart C, Cohen D, Bhattacharyya I, et al. Oral manifestations of Wegener's granulomatosis: a report of three cases and a literature review. J Am Dent Assoc. 2007;138(3):338-48. doi:10.14219/jada.archive.2007.0166; Patten SF, Tomecki KJ. Wegener's granulomatosis: cutaneous and oral mucosal disease. J Am Acad Dermatol. 1993;28(5):710-8. doi:10.1016/0190-9622(93)70098-E; Cohen RE, Cardoza TT, Drinnan AJ, et al. Gingival manifestations of Wegener's granulomatosis. J Periodontol. 1990;61(11):705-9. doi:10.1902/jop.1990.61.11.705; Shiboski CH, Regezi JA, Sanchez HC, Silverman S Jr. Oral lesions as the first clinical sign of microscopic polyangiitis: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;94(6):707-11. doi:10.1067/moe.2002.129178; Xing X, Zhang T, Wang X. Pediatric Wegener's granulomatosis with oral ulcers and progressive periodontitis: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112(4):1-5. doi:10.1016/j.tripleo.2011.05.030; Ruokonen H, Helve T, Arola J, et al. «Strawberry like» gingivitis being the first sign of Wegener's granulomatosis. Eur J Intern Med. 2009;20(6):651-3. doi:10.1016/j.ejim.2009.04.007; Siar CH, Yeo KB, Nakano K, et al. Strawberry gingivitis as the first presenting sign of Wegener's granulomatosis: report of a case. Eur J Med Res. 2011;16(7):331-4. doi:10.1186/2047-783X-16-7-331; Aravena V, Beltran V, Cantin M, Fuentes R. Gingival hyperplasia being the first sign of Wegener's granulomatosis. Intern J Clin Exper Med. 2014;7(8):2373-6.; Popa ER, Stegeman CA, Abdulahad WH, et al. Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. Rheumatology (Oxford). 2007;46(6):1029-33. doi:10.1093/rheumatology/kem022; Kitagawa K, Furuichi K, Sagara A, et al; Kanazawa Study Group for Renal Diseases and Hypertension. Risk factors associated with relapse or infectious complications in Japanese patients with microscopic polyangiitis. Clin Exp Nephrol. 2015 Nov 20. [Epub ahead of print]. PubMed PMID: 26590051.; Azarpazhooh A, Leake JL. Systematic review of the association between respiratory diseases and oral health. J Periodontol. 2006;77(9):1465-82. doi:10.1902/jop.2006.060010; Scannapieco FA, Ho AW. Potential associations between chronic respiratory disease and periodontal disease: analysis of National Health and Nutrition Examination Survey III. J Periodontol. 2001;72(1):50-6. doi:10.1902/jop.2001.72.1.50; Mojon P. Oral health and respiratory infection. J Can Dent Assoc. 2002;68(6):340-5.; Bosnjak A, Plancak D, Curilovic Z. Advances in the relationship between periodontitis and systemic diseases. Acta Stomatol Croat. 2001;35:267-71.; Inoue CN, Matsutani S, Ishidoya M, et al. Impact of periodontal treatment in combination with tonsillectomy plus methylprednisolone pulse therapy and angiotensin blockade for pediatric IgA nephropathy. Clin Nephrol. 2012;77(2):137-45. doi:10.5414/CN106836; Akman A, Kacaroglu H, Donmez L, et al. Relationship between periodontal findings and Behcet's disease: a controlled study. J Clin Periodontol. 2007;34(6):485-91. doi:10.1111/j.1600-051X.2007.01085.x; Karacayli U, Mumcu G, Simsek I, et al. The close association between dental and periodontal treatments and oral ulcer course in Behcet's disease: a prospective clinical study. J Oral Pathol Med. 2009;38(5):410-5. doi:10.1111/j.1600-0714.2009.00765.x; Loo JA, Yan W, Ramachandran P, Wong DT. Comparative human salivary and plasma proteomes. J Dent Res. 2010;89(10):1016-23. doi:10.1177/0022034510380414; Al Kawas S, Rahim ZH, Ferguson DB. Potential uses of human salivary protein and peptide analysis in the diagnosis of disease. Arch Oral Biol. 2012;57(1):1-9. doi:10.1016/j.archoralbio.2011.06.013; Yoshizawa JM, Schafer CA, Schafer JJ, et al. Salivary biomarkers: toward future clinical and diagnostic utilities. Clin Microbiol Rev. 2013;26(4):781-91. doi:10.1128/CMR.00021-13; Iwasaki K, Okawa-Takatsuji M, Aotsuka S, Ono T. Detection of anti-SS-A/Ro and anti-SS-B/La antibodies of IgA and IgG iso-types in saliva and sera of patients with Sjö gren's syndrome. Nihon Rinsho Meneki Gakkai Kaishi. 2003;26(6):346-54. doi:10.2177/jsci.26.346; Aqrawi LA, Skarstein K, Oijordsbakken G, Brokstad KA. Ro52-and Ro60-specific B cell pattern in the salivary glands of patients with primary Sjö gren's syndrome. Clin Exp Immunol. 2013;172(2):228-37. doi:10.1111/cei.12058; Janket S, Meurman JH, Baird AE, et al. Salivary immunoglobulins and prevalent coronary artery disease. J Dent Res. 2010;89(4):389-94. doi:10.1177/0022034509359884

Availability: https://rsp.mediar-press.net/rsp/article/view/2475
https://doi.org/10.14412/1995-4484-2017-685-689

Клінічний випадок атипового перебігу МПО-АНЦА-асоційованого васкуліту

Authors: Boiarchuk, O.R., Smiian, S.I.

Source: Zdorovʹe Rebenka, Vol 9, Iss 8.59, Pp 64-68 (2014)
CHILD`S HEALTH; № 8.59 (2014); 64-68
Здоровье ребенка-Zdorovʹe rebenka; № 8.59 (2014); 64-68
Здоров'я дитини-Zdorovʹe rebenka; № 8.59 (2014); 64-68

Subject Terms: системный васкулит, антинейтрофильные цитоплазматические антитела, миелопероксидаза, дети, antineutrophil cytoplasmic antibodies, systemic vasculitis, myeloperoxidase, children, системний васкуліт, антинейтрофільні цитоплазматичні антитіла, мієлопероксидаза, діти, Pediatrics, RJ1-570, 3. Good health

File Description: application/pdf

Access URL: https://doaj.org/article/915df839787f4419ad49f04ac4a333de
http://childshealth.zaslavsky.com.ua/article/download/75894/71424
https://paperity.org/p/241340261/case-report-of-atypical-course-of-mpo-anca-associated-vasculitis
http://childshealth.zaslavsky.com.ua/article/view/75894

EXPERIENCE WITH EFFECTIVE COMBINED ANTI-B-CELL THERAPY WITH RITUXIMAB AND BELIMUMAB FOR REFRACTORY GRANULOMATOSIS WITH POLYANGIITIS (WEGENER'S) WITH SEVERE LUNG DAMAGE ; Опыт эффективного применения комбинированной анти-В-клеточной терапии ритуксимабом и белимумабом при рефрактерном гранулематозе с полиангиитом (Вегенера) с тяжелым поражением легких

Authors: T. V. Beketova, M. Yu. Volkov, N. O. Nikonorova, T. M. Novoselova, Т. В. Бекетова, М. Ю. Волков, Н. О. Никонорова, Т. М. Новоселова

Source: Rheumatology Science and Practice; Vol 55, No 1 (2017); 104-109 ; Научно-практическая ревматология; Vol 55, No 1 (2017); 104-109 ; 1995-4492 ; 1995-4484 ; 10.14412/rjtao20171

Subject Terms: белимумаб, antineutrophil cytoplasmic antibodies, granulomatosis with polyangiitis, anti-B-cell therapy, rituximab, belimumab, антинейтрофильные цитоплазматические антитела, гранулематоз с полиангиитом, анти-В-клеточная терапия, ритуксимаб

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2345/1550; Luqmani RA, Suppiah R, Grayson PC, et al. Nomenclature and classification of vasculitis – update on the ACR/EULAR Diagnosis and Classification of Vasculitis Study (DCVAS). Clin Exper Immunol. 2011;164(s1):11-3. doi:10.1111/j.1365-2249.2011.04358.x; Jennette J, Falk R, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187-92. doi:10.1002/art.1780370206; Basu N, Watts R, Bajema I, et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis. 2010;69:1744-50. doi:10.1136/ard.2009.119032; Guerry M, Brogan P, Bruce I, et al. Recommendations for the use of rituximab in anti- neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012;51(4):634-43. doi:10.1093/rheumatology/ker150; Насонов ЕЛ, редактор. Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Москва: ИМА-Пресс; 2012. 343 с. [Nasonov EL, editor. Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B-cell therapy in rheumatology: Focus on rituximab]. Moscow: IMA-Press; 2012. 343 p.].; Lane S, Watts R, Shepstone L, et al. Primary systemic vasculitis: clinical features and mortality. QJM. 2005;98:97-111. doi:10.1093/qjmed/hci015; Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Int Med. 1992;116:488-98. doi:10.7326/0003-4819-116-6-488; Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 2000;43(9):2025-33. doi:10.1002/1529-0131(200009)43:93.0.CO;2-O; Slot MC, Tervaert JW, Boomsma MM, et al. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum. 2004;51(2):269-73. doi:10.1002/art.20234; Holle JU, Dubrau C, Herlyn K, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis. 2012;71(3):327-33. doi:10.1136/ard.2011.153601; Malm IJ, Mener DJ, Kim J, et al. Otolaryngological progression of granulomatosis with polyangiitis after systemic treatment with rituximab. Otolaryngol Head Neck Surg. 2014;150(1):68-72. doi:10.1177/0194599813509784; Бекетова ТВ, Насонов ЕЛ, Александрова ЕН и др. Российский опыт применения моноклональных антител к В-лимфоцитам (Ритуксимаб) при системных васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами (предварительные результаты российского регистра НОРМА). Научно-практическая ревматология. 2014;52(2):147-59 [Beketova TV, Aleksandrova EN, Novoselova TM, et al. Russian experience with using monoclonal antibodies to B-lymphocytes (rituximab) in systemic vasculitides associated with neutrophil cytoplasmic antibodies (preliminary results of the Russian Register NORMA). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(2):147-58 (In Russ.)]. doi:10.14412/1995-4484-2014-147-158; Stone JH, Merkel PA, Spiera R, et al. RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-32. doi:10.1056/NEJMoa0909905; Jones RB, Tervaert JW, Hauser T, et al; European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211-20. doi:10.1056/NEJMoa0909169; Guillevin L, Pagnoux C, Karras A, et al; French Vasculitis Study Group. Rituximab versus azathioprine for maintenance in ANCAassociated vasculitis. N Engl J Med. 2014;371(19):1771-80. doi:10.1056/NEJMoa1404231; Manzi S, Sanchez-Guerrero J, Merrill JT, et al. BLISS-52 and BLISS-76 Study Groups: Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833-8. doi:10.1136/annrheumdis-2011-200831; Navarra SV, Guzman RM, Gallacher AE, et al. BLISS-52 Study Group: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo- controlled, phase 3 trial. Lancet. 2011;377(9767):721-31. doi:10.1016/S0140-6736(10)61354-2; Furie R, Petri M, Zamani E, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918-30. doi:10.1002/art.30613; Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in the patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(7):2328-37. doi:10.1002/art.34400; Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov. 2006;5(7):564-76. doi:10.1038/nrd2085; Dö rner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol. 2009;5(8):433-41. doi:10.1038/nrrheum.2009.141; Silverman GJ. Therapeutic B cell depletion and regeneration in rheumatoid arthritis. Emerging patterns and paradigms. Arthritis Rheum. 2006;54(8):2356-67. doi:10.1002/art.22020; Меснянкина АА. Клеточные и молекулярные биомаркеры и потенциальные терапевтические мишени при системной красной волчанке. Научно-практическая ревматология. 2016;54(2):206-18 [Mesnyankina AA. Cellular and molecular biomarkers and potential therapeutic targets in systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(2):206-18 (In Russ.)]. doi:10.14412/1995-4484-2016-206-218; Супоницкая ЕВ, Александрова ЕН, Насонов ЕЛ. Клиническое значение BAFF/BLyS и APRIL при системной красной волчанке и ревматоидном артрите. Научно- практическая ревматология. 2014;52(5):545-52 [Suponitskya EV, Aleksandrova EN, Nasonov EL. Clinical significance of BAFF/BLyS and APRIL in systemic lupus erythematosus and rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(5):545-52 (In Russ.)]. doi:10.14412/1995-4484-2014-545-552; Bekar KW, Owen T, Dunn R, et al. Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum. 2010;62:2443- 57. doi:10.1002/art.27515; Lamprecht P, Gross WL, Kabelitz D, et al. T cell alterations and lymphoid neogenesis favoring autoimmunity in Wegener's granulomatosis. Arthritis Rheum. 2007;56:1725-7. doi:10.1002/art.22693; Voswinkel J, Mü ller A, Lamprecht P. Is PR3-ANCA formation initiated in Wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production. Ann N Y Acad Sci. 2005;1051:12-9. doi:10.1196/annals.1361.042; Zhao Y, Odell E, Choong LM, et al. Granulomatosis with polyangiitis involves sustained mucosal inflammation that is rich in B-cell survival factors and autoantigen. Rheumatology (Oxford). 2012;51(9):1580-6. doi:10.1093/rheumatology/kes123; Ferraro AJ, Smith SW, Neil D, et al. Relapsed Wegener's granulomatosis after rituximab therapy – B cells are present in new pathological lesions despite persistent 'depletion' of peripheral blood. Nephrol Dial Transplant. 2008;23:3030-2. doi:10.1093/ndt/gfn318; Vital EM, Dass S, Buch MH, et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum. 2011;63:3038-47. doi:10.1002/art.30466; Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol. 2007;122:62-74. doi:10.1016/j.clim.2006.08.016; Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 2007;56:3044-56. doi:10.1002/art.22810; Супоницкая ЕВ, Александрова ЕН, Алексанкин АП, Насонов ЕЛ. Гомеостаз В- лимфоцитов и направления анти-В-клеточной терапии при ревматоидном артрите. Научно-практическая ревматология. 2013;51(4):432-8 [Suponitskaya EV, Aleksandrova EN, Aleksankin AP, Nasonov EL. B-lymphocyte hemostasis and anti-B-cell therapy areas for rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(4):432-8 (In Russ.)]. doi:10.14412/1995-4484-2013-1256; Супоницкая ЕВ, Александрова ЕН, Алексанкин АП, Насонов ЕЛ. Влияние терапии генно-инженерными биологическими препаратами на субпопуляции В-лимфоцитов при ревматических заболеваниях: новые данные. Научно-практическая ревматология. 2015;53(1):78-83 [Suponitskaya EV, Aleksandrova EN, Aleksankin AP, Nasonov EL. Impact of therapy with biological agents on B-lymphocyte subpopulations in rheumatic diseases: New evidence. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(1):78-83 (In Russ.)]. doi:10.14412/1995-4484-2015-78-83; Rauch M, Tussiwand R, Bosco N, et al. Crucial role for BAFFBAFF-R signaling in the survival and maintenance of mature B cells. PLoS One. 2009;4(5):e5456. doi:10.1371/journal.pone.0005456; Witko-Sarsat V, Daniel S, Noë l L, et al. Neutrophils and B lymphocytes in ANCA associated vasculitis. APMIS. 2009;117:27-33. doi:10.1111/j.1600-0463.2009.02473.x; Holden NJ, Williams JM, Morgan MD, et al. ANCA-stimulated neutrophils release BLyS and promote B-cell survival: a clinically relevant cellular process. Ann Rheum Dis. 2011;70(12):2229-33. doi:10.1136/ard.2011.153890; Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues selfreactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004;20(6):785-98. doi:10.1016/j.immuni.2004.05.010; Ota M, Duong BH, Torkamani A, et al. Regulation of the B-cell receptor repertoire and self-reactivity by BAFF. J Immunol. 2010;185(7):4128-36. doi:10.4049/jimmunol.1002176; Lenert A, Lenert P. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug Des Devel Ther. 2015;9:333-47. doi:10.2147/DDDT.S67264; Cornec D, Avouac J, Youinou P, et al. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev. 2009;8(6):515-9. doi:10.1016/j.autrev.2009.01.007; Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003;48(12):3475-86. doi:10.1002/art.11354; Edberg JC, Zhou T, Aksi K, et al. Levels of circulating B lymphocyte stimulator (BLys) are elevated in patients with Wegener's granulomatosis (abstract). Kidney Blood Press Res. 2004;26:256.; Krumbholz M, Specks U, Wick M, et al. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun. 2005;25(4):298-302. doi:10.1016/j.jaut.2005.08.004; Xin G, Chen M, Su Y, et al. Serum B-cell activating factor in myeloperoxidase- antineutrophil cytoplasmic antibodies-associated vasculitis. Am J Med Sci. 2014;348(1):25-9. doi:10.1097/MAJ.0b013e3182a55ab6; Nagai M, Hirayama K, Ebihara I, et al. Serum levels of BAFF and APRIL in myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis: association with disease activity. Nephron Clin Pract. 2011;118(4):c339-45. doi:10.1159/000323393; Bader L, Koldingsnes W, Nossent J. B-lymphocyte activating factor levels are increased in patients with Wegener's granulomatosis and inversely correlated with ANCA titer. Clin Rheumatol. 2010;29(9):1031-5. doi:10.1007/s10067-010-1526-z; Schneeweis C, Rafalowicz M, Feist E, et al. Increased levels of BLyS and sVCAM-1 in anti- neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV). Clin Exp Rheumatol. 2010;28(1 Suppl 57):62-6.; Sanders JS, Huitma MG, Kallenberg CG, et al. Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B-cell activator of the tumor necrosis factor family during followup in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapse. Ann Rheum Dis. 2006;65(11):1484-9. doi:10.1136/ard.2005.046219; Scapini P, Hu Y, Chu CL, et al. Myeloid cells, BAFF, and IFN-{gamma} establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice. J Exp Med. 2010;207:1757-73. doi:10.1084/jem.20100086; Hilhorst M, Shirai T, Berry G, et al. T cell-macrophage interactions and granuloma formation in vasculitis. Front Immunol. 2014(Sep)12;5:432.; Jacobi AM, Huang W, Wang T, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010;62(1):201-10. doi:10.1002/art.27189; Kreuzaler M, Rauch M, Salzer U, et al. Soluble BAFF levels inversely correlate with peripheral B-cell numbers and the expression of BAFF receptors. J Immunol. 2012;188(1):497-503. doi:10.4049/jimmunol.1102321; Vallerskog T, Heimbü rger M, Gunnarsson I, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther. 2006;8(6):R167. doi:10.1186/ar2076; Vital E, Cuthbert R, Horner E, et al. High serum B-cell activating factor (BAFF) predicts good clinical response to rituximab in RA: pilot data. Ann Rheum Dis. 2010;69:A11-2. doi:10.1136/ard.2010.129585b; Pollard RP, Abdulahad WH, Vissink A, et al. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebocontrolled clinical trial. Ann Rheum Dis. 2013;72(1):146-8. doi:10.1136/annrheumdis-2012-202071; Lavie F, Miceli-Richard C, Ittah M, et al. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis. 2007;66:700-3. doi:10.1136/ard.2006.060772; Wei YL, Seshasayee D, Lee WP, et al. Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus. Arthritis Rheum. 2015;67(1):215-24. doi:10.1002/art.38907; Kraaij T, Huizinga TW, Rabelink TJ, et al. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology (Oxford). 2014;53:2122-4. doi:10.1093/rheumatology/keu369; Simonetta F, Allali D, Roux-Lombard P, et al. Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab. Joint Bone Spine. 2016 May 26. pii: S1297-319X(16)30020-3. doi:10.1016/j.jbspin.2016.01.008; De Vita S, Quartuccio L, Salvin S, et al. Sequential therapy with belimumab followed by rituximab in Sjö gren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy. Clin Exp Rheumatol. 2014;32(4):490-4.

Availability: https://rsp.mediar-press.net/rsp/article/view/2345
https://doi.org/10.14412/1995-4484-2017-104-109

THE 2016 EUROPEAN (EULAR/ERA-EDTA) RECOMMENDATIONS FOR THE DIAGNOSIS AND MANAGEMENT OF ANCA-ASSOCIATED SYSTEMIC VASCULITIS ; Европейские (EULAR/ERA-EDTA) рекомендации по диагностике и лечению АНЦА-ассоциированных системных васкулитов – 2016

Authors: T. V. Beketova, Т. В. Бекетова

Source: Rheumatology Science and Practice; Vol 55, No 1 (2017); 12-16 ; Научно-практическая ревматология; Vol 55, No 1 (2017); 12-16 ; 1995-4492 ; 1995-4484 ; 10.14412/rjtao20171

Subject Terms: ритуксимаб, antineutrophil cytoplasmic antibodies, granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, rituximab, антинейтрофильные цитоплазматические антитела, гранулематоз с полиангиитом (Вегенера), микроскопический полиангиит, эозинофильный гранулематоз с полиангиитом

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2332/1537; Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Jun 23. pii: annrheumdis- 2016-209133. doi:10.1136/annrheumdis-2016-209133; Aasarod K, Bostad L, Hammerstrom J, et al. Renal histopathology and clinical course in 94 patients with Wegener's granulomatosis. Nephrol Dial Transplant. 2001;16:953-60. doi:10.1093/ndt/16.5.953; Schnabel A, Holl-Ulrich K, Dalhoff K, et al. Efficacy of transbronchial biopsy in pulmonary vaculitides. Eur Respir J. 1997;10:2738-43. doi:10.1183/09031936.97.10122738; Corapi KM, Chen JL, Balk EM, et al. Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. Am J Kidney Dis. 2012;60:62-73. doi:10.1053/j.ajkd.2012.02.330; De Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized rial. Ann Intern Med. 2009;150:670-80. doi:10.7326/0003-4819-150-10-200905190-00004; Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum. 1997;40:2187- 98. doi:10.1002/1529-0131(199712)40:123.0.CO;2-H; Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for nduction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis. 2012;71:955-60. doi:10.1136/annrheumdis-2011-200477; Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA- associated renal vasculitis. N Engl J Med. 2010;363:211-20. doi:10.1056/NEJMoa0909169; Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA- associated vasculitis. N Engl J Med. 2010;363:221-32. doi:10.1056/NEJMoa0909905; De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:2461-9. doi:10.1002/art.21142; Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum. 2000;43:1836-40. doi:10.1002/1529- 0131(200008)43: 83.0.CO;2-R; Metzler C, Hellmich B, Gause A, et al. Churg Strauss syndrome – successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol. 2004;22(6 Suppl.):S-52-61.; Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A data-driven review. Arthritis Rheum. 2010;62:9-21. doi:10.1002/art.25061; Miloslavsky EM, Specks U, Merkel PA, et al. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Arthritis Rheum. 2015;67:1629-36. doi:10.1002/art.39104; Klemmer PJ, Chalermskulrat W, Reif MS, et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with Small-Vessel vasculitis. Am J Kidney Dis. 2003;42:1149-53.doi:10.1053/j.ajkd.2003.08.015; Levy JB, Hammad T, Coulthart A, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 2004;66:1535-40. doi:10.1111/j.1523-1755.2004.00917.x; Metzler C, Miehle N, Manger K, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford). 2007;46:1087-91. doi:10.1093/rheumatology/kem029; Stegeman CA, Tervaert JWC, de Jong PE, et al. Trimethoprimsulfamethoxazole (Co- trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med. 1996;335:16-20. doi:10.1056/NEJM199607043350103; Springer J, Nutter B, Langford CA, et al. Granulomatosis with polyangiitis (Wegener's): impact of maintenance therapy duration. Medicine (Baltimore). 2014;93:82-90. doi:10.1097/MD.0000000000000020; Walsh M, Merkel PA, Mahr A, et al. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res (Hoboken). 2010;62:1166-73. doi:10.1002/acr.20176; Pagnoux C, Hogan SL, Chin H, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibodyassociated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 2008;58:2908-18. doi:10.1002/art.23800; Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibodyassociated vasculitis. Ann Rheum Dis. 2007;66:605-17. doi:10.1136/ard.2006.062711; Holle JU, Voigt C, Both M, et al. Orbital masses in granulomatosis with polyangiitis are associated with a refractory course and a high burden of local damage. Rheumatology (Oxford). 2013;52:875-82. doi:10.1093/rheumatology/kes382; Pullerits R, Ljevak M, Vikgren J, et al. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)- associated vasculitis: long-term follow-up from a single centre. Scand J Immunol. 2012;76:411-20. doi:10.1111/j.1365-3083.2012.02747.x; Seror R, Pagnoux C, Ruivard M, et al. Treatment strategies and outcome of induction- refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial. Ann Rheum Dis. 2010;69:2125-30. doi:10.1136/ard.2010.131953; Fortin PM, Tejani AM, Bassett K, et al. Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis. Cochrane Database Syst Rev. 2013;1:CD007057. doi:10.1002/14651858.CD007057.pub3; Тomasson G, Grayson PC, Mahr AD, et al. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis – a meta-analysis. Rheumatology (Oxford). 2012;51:100-9. doi:10.1093/rheumatology/ker280; Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med. 2007;120:643.e9-14. doi:10.1016/j.amjmed.2006.08.016; Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68:1827-32. doi:10.1136/ard.2008.101279; Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40:371-80. doi:10.1002/art.1780400222; Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine. 2011;90:19-27. doi:10.1097/MD.0b013e318205a4c6; De Groot K, Gross WL, Herlyn K, Reinhold-Keller E. Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol. 2001;55(1):31-8.; Alberici F, Smith RM, Jones RB, et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford). 2015;54:1153-60. doi:10.1093/rheumatology/keu452; Suppiah R, Judge A, Batra R, et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken). 2011;63:588-96. doi:10.1002/acr.20433

Availability: https://rsp.mediar-press.net/rsp/article/view/2332
https://doi.org/10.14412/1995-4484-2017-12-16

THE VALUE OF THE RUSSIAN NATIONAL REGISTRY OF PATIENTS WITH ANCA-ASSOCIATED SYSTEMIC VASCULITIS AS AN INNOVATIVE TOOL OF PERSONALIZED INDUCTION AND MAINTENANCE THERAPY ; ЗНАЧЕНИЕ НАЦИОНАЛЬНОГО РЕГИСТРА БОЛЬНЫХ АНЦА-АССОЦИИРОВАННЫМИ СИСТЕМНЫМИ ВАСКУ ЛИТАМИ КАК ИННОВАЦИОННОГО ИНСТРУМЕНТА ПЕРСОНИФИЦИРОВАННОЙ ИНДУКЦИОННОЙ И ПОДДЕРЖИВАЮЩЕЙ ТЕРАПИИ

Authors: T. V. Beketova, Т. В. Бекетова

Source: Rheumatology Science and Practice; Vol 54, No 5 (2016); 499-507 ; Научно-практическая ревматология; Vol 54, No 5 (2016); 499-507 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20165

Subject Terms: «Лечение до достижения цели», antineutrophil cytoplasmic antibodies, Russian National Registry of patients with ANCA-associated systemic vasculitides, follow-up, treatment-to-target, антинейтрофильные цитоплазматические антитела, Национальный регистр больных АНЦА-ассоциированными системными васкулитами, динамическое наблюдение

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2289/1493; Basu N, Watts R, Bajema I, et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis. 2010;69:1744-50. doi:10.1136/ard.2009.119032; Scott DG, Watts RA. Systemic vasculitis: epidemiology, classification and environmental factors. Ann Rheum Dis. 2000 Mar;59(3):161-3. doi:10.1136/ard.59.3.161; Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Jun 23. doi:10.1136/annrheumdis-2016-209133; Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015;26(7):545-53. doi:10.1016/j.ejim.2015.04.022; Moosig F, Bremer JP, Hellmich B, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg–Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis. 2013;72(6):1011-7. doi:10.1136/annrheumdis-2012- 201531; Ntatsaki E, Carruthers D, Chakravarty K, et al. BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford). 2014;53(12):2306-9. doi:10.1093/rheumatology/ket445; Бекетова ТВ, Александрова ЕН, Новоселова ТМ и др. Российский опыт применения моноклональных антител к В-лимфоцитам (ритуксимаб) при системных васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами (предварительные результаты российского регистра НОРМА). Научнопрактическая ревматология. 2014;52(2):147-58 [Beketova TV, Aleksandrova EN, Novoselova TM, et al. Russian experience with using monoclonal antibodies to b-lymphocytes (rituximab) in systemic vasculitides associated with neutrophil cytoplasmic antibodies (preliminary results of the russian register NORMA). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(2):147-58 (In Russ.)]. doi:10.14412/1995-4484-2014-147-158; Luqmani RA. Treat-to-target in vasculitis: is this a sensible approach? Clin Exp Rheumatol. 2012;30 Suppl 73:149-53.; Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994 Nov;87(11):671-8.; Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997 Feb;40(2):371-80. doi:10.1002/art.1780400222; Koutantji M, Harrold E, Lane SE, et al. Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis. Arthritis Rheum. 2003;49:826-37. doi:10.1002/art.11471; Новик АА, Ионова ТИ. Руководство по исследованию качества жизни в медицине. Москва: ОЛМА-ПРЕСС; 2002. 314 с. [Novik AA, Ionov TI. Rukovodstvo po issledovaniyu kachestva zhizni v meditsine [Guide to the study of quality of life in medicine]. Moscow: Olma-Press; 2002. 314 p.].; Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66:605-17. doi:10.1136/ard.2006.062711; Merkel PA, Aydin SZ, Boers M, et al. The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. J Rheumatol. 2011 Jul;38(7):1480-6. doi:10.3899/jrheum.110276; Mukhtyar C, Guillevin L, Cid M, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68:310-7. doi:10.1136/ard.2008.088096; Lapraik C, Watts R, Bacon P, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford). 2007;46:1615-6. doi:10.1093/rheumatology/kem146a; Suka M, Hayashi T, Kobayashi S, et al. Improvement in health-related quality of life in MPO-ANCA-associated vasculitis patients treated with cyclophosphamide plus prednisolone: an analysis of 18 months of follow-up data from the JMAAV study. Mod Rheumatol. 2012 Nov;22(6):877-84. doi:10.1007/s10165-012-0602-4; Alexander DS, Hogan SL, Jordan JM, et al. The relationship between peer support, medication adherence, and quality of life among patients with vasculitis. Clin Exp Rheumatol. 2015 Mar-Apr;33(2 Suppl 89):S185-6. Epub 2015 May 26.; Walsh M, Mukhtyar C, Mahr A, et al. Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken). 2011 Jul;63(7):1055-61. doi:10.1002/acr.20471; Allen SD, Harvey CJ. Imaging of Wegener’s granulomatosis. Br J Radiol. 2007 Sep;80(957):757-65. doi:10.1259/bjr/34705892; Murphy JM, Balan KK, Toms A, et al. Radiolabeled leucocyte imaging in diffuse granulomatous involvement of the meninges in Wegener’s granulomatosis: scintigraphic findings and their role in monitoring treatment response to specific immunotherapy (humanized monoclonal antilymphocyte antibodies). AJNR Am J Neuroradiol. 2000;21(8):1460-520.; Tomasson G, Grayson PC, Mahr AD, et al. Value of ANCA measurements during remission to predict a relapse of ANCAassociated vasculitis – a meta-analysis. Rheumatology (Oxford). Jan;51(1):100-9. doi:10.1093/rheumatology/ker280; Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 2000 Sep;43(9):2025-33. doi:10.1002/1529-0131(200009)43:93.0.CO;2-O; Slot MC, Tervaert JW, Boomsma MM, Stegeman CA. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum. 2004 Apr 15;51(2):269-73. doi:10.1002/art.20234; Stegeman C, Tervaert J, Sluiter W, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med. 1994;120:12-7. doi:10.7326/0003-4819-120-1-199401010-00003; Guillevin L, Cordier J, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum. 1997;40:2187-98. doi:10.1002/art.1780401213; Семенкова ЕН. Системные некротизирующие васкулиты. Москва: Русский врач; 2001. 96 с. [Semenkova EN. Sistemnye nekrotiziruyushchie vaskulity [Systemic necrotizing vasculitis]. Moscow: Russian doctor; 2001. 96 p.].; Groot K, Harper L, Jayne D, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis. A randomized trial. Ann Intern Med. 2009;150:670-80. doi:10.7326/0003-4819-150-10-200905190-00004; Бекетова ТВ. Гранулематоз с полиангиитом, патогенетически связанный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения. Научно-практическая ревматология. 2012; 50(6):19-28 [Beketova TV. Granulomatosis with polyangiitis, which is pathogenetically associated with antineutrophil cytoplasmic antibodies: clinical features. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(6):19-28 (In Russ.)]. doi:10.14412/1995-4484-2012-1288; Flossmann O, Berden A, de Groot K, et al.; European Vasculitis Study Group. Long-term patient survival in ANCAassociated vasculitis. Ann Rheum Dis. 2011 Mar;70(3):488-94. doi:10.1136/ard.2010.137778; Luqmani R, Suppiah R, Edwards CJ, et al. Mortality in Wegener’s granulomatosis: a bimodal pattern. Rheumatology (Oxford). 2011 Apr;50(4):697-702. doi:10.1093/rheumatology/keq351; Ollenschlä ger G, Kirchner H, Fiene М. Leitlinien in der Medizin-scheitern sie an der praktischen Umsetzung? Der Internist. 2001;42(4):473-83.; Raimundo K, Farr AM, Kim G, Duna G. Clinical and economic burden of antineutrophil cytoplasmic antibody-associated vasculitis in the United States. J Rheumatol. 2015;42(12):2383-91. doi:10.3899/jrheum.150479; Jones RB, Tervaert JW, Hauser T, et al.; European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCAassociated renal vasculitis. N Engl J Med. 2010;363(3):211-20. doi:10.1056/NEJMoa0909169; Stone JH, Merkel PA, Spiera R, et al.; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-32. doi:10.1056/NEJMoa0909905; Guerry M-J, Brogan P, Bruce I, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibodyassociated vasculitis. Rheumatology. 2012;51:634-43. doi:10.1093/rheumatology/ker150; Langford С. Cyclophosphamide as induction therapy for Wegener’s granulomatosis and microscopic polyangiitis. Clin Exp Immunol. 2011 May;164 Suppl 1:31-4. doi:10.1111/j.1365-2249.2011.04364.x; Silva-Fernandez L, Loza E, Martinez-Taboada VM, et al.; Systemic Autoimmune Diseases Study Group of the Spanish Society for Rheumatology (EAS-SER). Biological therapy for systemic vasculitis: a systematic review. Semin Arthritis Rheum. 2014 Feb;43(4):542-57. doi:10.1016/j.semarthrit.2013.07.010. Epub 2013 Aug 24.; Donvik К, Omdal R. Churg-Strauss syndrome successfully treated with rituximab. Rheum Int. 2009;31:89-91. doi:10.1007/s00296-009-1146-6; Cartin-Ceba R, Keogh K, Specks U, et al. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant. 2011;26:2865-71. doi:10.1093/ndt/gfq852; Kronbichler A, Jayne DR. Con: Should all patients with antineutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab? Nephrol Dial Transplant. 2015 Jul;30(7):1075-81. doi:10.1093/ndt/gfv216; Timlin H, Lee SM, Manno RL, et al. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis. Semin Arthritis Rheum. 2015 Aug;45(1):67-9. doi:10.1016/j.semarthrit.2015.02.005; Pagnoux C, Hogan S, Chin H, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibodyassociated small-vessel vasculitis: Comparison of two independent cohorts. Arthritis Rheum. 2008;58:2908-18. doi:10.1002/art.23800; Alberici F, Smith RM, Jones RB, et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford). 2015 Jul;54(7):1153-60. doi:10.1093/rheumatology/keu452; Kartin-Seba R, Goldbin J, Keoch KA, et al. Rituximab for emmission, induction and maintenance in ANCA-associated vasculitis: a single centered 10-year experience in 108 patients. Arthritis Rheum. 2010;62 Suppl 10:680.; Latimer NR, Carroll C, Wong R, et al. Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal. Pharmacoeconomics. 2014 Dec;32(12):1171-83. doi:10.1007/s40273-014-0189-z; Gregersen JW, Chaudhry A, Jayne DR, et al. Rituximab for ANCA-associated vasculitis in the setting of severe infection. Scand J Rheumatol. 2013;42(3):207-10. doi:10.3109/03009742.2012.739638; Bomback AS, Appel GB, Radhakrishnan J, et al. ANCA-associated glomerulonephritis in the very elderly. Kidney Int. 2011;79:757-64. doi:10.1038/ki.2010.489; Van Oers MH, van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular nonHodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28:2853-8. doi:10.1200/JCO.2009.26.5827; Weidner S, Geuss S, Hafezi-Rachti S, et al. ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant. 2004;19:1403-11. doi:10.1093/ndt/gfh161; Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36-44. doi:10.1056/NEJMoa020286; Robson J, Doll H, Suppiah R, et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford). 2015;54(3):471-81. doi:10.1093/rheumatology/keu366; Turner-Stokes T, Sandhu E, Pepper RJ, et al. Induction treatment of ANCA-associated vasculitis with a single dose of rituximab. Rheumatology (Oxford). 2014 Aug;53(8):1395-403. doi:10.1093/rheumatology/ket489; Exley AR, Bacon PA, Luqmani RA, et al. Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Br J Rheumatol. 1998;37:57-63. doi:10.1093/rheumatology/37.1.57; Talar-Williams C, Hijazi Y, Walther M, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996;124:477-84. doi:10.7326/0003-4819-124-5-199603010-00003; Hoffman G, Kerr G, Leavitt R, et al. Wegener granulomatosis: An analysis of 158 patients. Ann Intern Med. 1992;116:488-98. doi:10.7326/0003-4819-116-6-488; Стрижаков ЛА, Моисеев СВ, Коган ЕА и др. Поражение сердца при системных васкулитах: патогенетические звенья, значение факторов риска развития сердечнососудистых осложнений и диагностика. Терапевтический архив. 2014;12(2):35-42 [Strizhakov LA, Moiseev SV, Kogan EA, et al. Heart disorders in systemic vasculitis: Pathogenetic links, importance of risk factors for cardiovascular complications and diagnostics. Terapevticheskiy Arkhiv. 2014;12(2):35-42 (In Russ.)].; Suppiah R, Judge A, Batra R, et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener’s granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken). 2011;63:588-96. doi:10.1002/acr.20433; Little MA, Nightingale P, Verburgh CA, et al.; European Vasculitis Study (EUVAS) Group. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2010;69:1036-43. doi:10.1136/ard.2009.109389; Bosch X, Guilabert А, Espinosa G, et al. Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. JAMA. 2007;298:655-69. doi:10.1001/jama.298.6.655; Le Guenno G, Mahr A, Pagnoux C, et al. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum. 2011;63:1435-45. doi:10.1002/art.30296; Knight A, Askling J, Granath F, et al. Urinary bladder cancer in Wegener’s granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis. 2004;63:1307-11. doi:10.1136/ard.2003.019125; Monach P, Arnold L, Merkel P. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62:9-21. doi:10.1002/art.25061; Данилов ДС. Терапевтическое сотрудничество (комплаенс): содержание понятия, механизмы формирования и методы оптимизации. Неврология, нейропсихиатрия, психосоматика. 2014;6(2):4-12 [Danilov D. Therapeutic collaboration (compliance): Content of the definition, mechanisms of formation, and methods of optimization. Nevrologiya, Neyropsikhiatriya, Psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2014;6(2):4-12 (In Russ.)]. doi:10.14412/2074-2711-2014-2-4-12; Carpenter DM, Kadis JA, Devellis RF, et al. The effect of medication-related support on the quality of life of patients with vasculitis in relapse and remission. J Rheumatol. 2011;38(4):709-15. doi:10.3899/jrheum.100808; Pepper JK, Carpenter DM, DeVellis RF. Does adherencerelated support from physicians and partners predict medication adherence for vasculitis patients? J Behav Med. 2012;35(2):115-23. doi:10.1007/s10865-012-9405-5; Carpenter DM, Hogan SL, Devellis RF. Predictors of medication non-adherence for vasculitis patients. Clin Rheumatol. 2013 May;32(5):649-57. doi:10.1007/s10067-013-2164-z; Park DC, Hertzog C, Leventhal H, et al. Medication adherence in rheumatoid arthritis patients: older is wiser. J Am Geriatr Soc. 1999;47(2):172-83. doi:10.1111/j.1532-5415.1999.tb04575.x; Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med. 1990;150(7):1509-10. doi:10.1001/archinte.1990.00390190143023; McKinney EF, Lyons PA, Carr EJ, et al. A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med. 2010;16(5):586-91, 1p following 591. doi:10.1038/nm.2130

Availability: https://rsp.mediar-press.net/rsp/article/view/2289
https://doi.org/10.14412/1995-4484-2016-499-507

THE ONSET OF ANCA-ASSOCIATED SYSTEMIC VASCULITIS MASKING RHEUMATOID ARTHRITIS ; Дебют АНЦА-ассоциированного системного васкулита под маской ревматоидного артрита

Authors: N. F. Frolova, L. V. Korsakova, E. S. Stolyarevich, N. O. Nikonorova, T. V. Beketova, Н. Ф. Фролова, Л. В. Корсакова, Е. С. Столяревич, Н. О. Никонорова, Т. В. Бекетова

Source: Rheumatology Science and Practice; Vol 53, No 6 (2015); 653-656 ; Научно-практическая ревматология; Vol 53, No 6 (2015); 653-656 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20156

Subject Terms: антитела к циклическому цитруллинированному пептиду, antineutrophil cytoplasmic antibodies, microscopic polyangiitis, granulomatosis with polyangiitis, rheumatoid arthritis, anticyclic citrullinated peptide antibodies, антинейтрофильные цитоплазматические антитела, микроскопический полиангиит, гранулематоз с полиангиитом, ревматоидный артрит

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2158/1381; Jennette J, Falk R, Bacon P, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2012;65:1–11. doi:10.1002/art.37715; Savage C, Winearls C, Evans D, et al. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med. 1985;56:467–83.; Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999;42:421–30. doi:10.1002/1529-0131(199904)42:33.0.CO;2-6; Ahn J, Hwang J, Lee J, et al. Clinical features and outcome of microscopic polyangiitis under a new consensus algorithm of ANCA-associated vasculitides in Korea. Rheumatol Int. 2011;32:2979–86. doi:10.1007/s00296-011-2079-4; Rodgers H, Guthrie J, Brownjohn A, Turney J. Microscopic polyarteritis: clinical features and treatment. Postgrad Med J. 1989;65:515–8. doi:10.1136/pgmj.65.766.515; Pagnoux C, Seror R, Berezne A, et al. Remittent non-destructive polysynovitis in P-ANCA-positive vasculitis patients with anti-CCP antibodies. Joint Bone Spine. 2010;77(6):604–7. doi:10.1016/j.jbspin.2010.02.013; Бекетова ТВ. Микроскопический полиангиит, ассоциированный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения. Терапевтический архив. 2015;(5):33–46 [Beketova TV. Microscopic polyangiitis associated with anti-neutrophil cytoplasmic antibody: clinical features. Terapevticheskii arkhiv. 2015;(5):33–46 (In Russ.)].; Бекетова ТВ. Гранулематоз с полиангиитом, патогенетически связанный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения. Научно-практическая ревматология. 2012;50(6):19–28 [Beketova TV. Granulomatosis with polyangiitis, which is pathogenetically associated with antineutrophil cytoplasmic antibodies: clinical features. Nauchno-prakticheskaya revmatologiya =Rheumatology Science and Practice. 2012;50(6):19–28 (In Russ.)].; Noritake D, Weiner S, Bassett L, et al. Rheumatic manifestations of Wegener’s granulomatosis. J Rheumatol. 1987;4(5):949–51.; Tervaert JWC, Damoiseaux J, Boomsma MM, Stegeman CA. Absence of anti-cyclic citrullinated peptide antibodies in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2002;46:849–50. doi:10.1002/art.10087; Elkayam O, Segal R, Lidgi M, et al. Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis. Ann Rheum Dis. 2006;65:1110–2. doi:10.1136/ard.2005.045229; Singh S, Singh U, Kunwar А, Chaurasia N. Anti CCP antibody assay: a diagnostic dilemma in diagnosis of tubercular synovitis. World J Pathol. 2014;3:38–44.; Бадокин ВВ, Трошкина ИА, Александрова ЕН. Ревматоидный фактор и антитела к циклическому цитруллинированному пептиду у больных с псориатическим артритом. Научно-практическая ревматология. 2011;(5):32–7 [Badokin VV, Troshkina IA, Alexandrova EN. Rheumatoid factor and anti-cyclic citrullinated peptide antibodies in patients with psoriatic arthritis. Nauchno-prakticheskaya revmatologiya =Rheumatology Science and Practice. 2011;(5):32–7 (In Russ.)].; Vannini A, Cheung K, Fusconi M, et al. Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: citrulline-dependent or not? Ann Rheum Dis. 2007;66(4):511–6. doi:10.1136/ard.2006.058933; Aletaha D, Neogi T, Silman A, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81. doi:10.1002/art.27584

Availability: https://rsp.mediar-press.net/rsp/article/view/2158
https://doi.org/10.14412/1995-4484-2015-633-656

PROBLEMS IN THE DIAGNOSIS AND TREATMENT OF ANCA-ASSOCIATED SYSTEMIC VASCULITIS: IN THE FOCUS OF ANCA-NEGATIVE PAUCI-IMMUNE GLOMERULONEPHRITIS ; ПРОБЛЕМЫ ДИАГНОСТИКИ И ЛЕЧЕНИЯ АНЦА-АССОЦИИРОВАННЫХ СИСТЕМНЫХ ВАСКУЛИТОВ: В ФОКУСЕ АНЦА-НЕГАТИВНЫЙ PAUCI-ИММУННЫЙ ГЛОМЕРУЛОНЕФРИТ

Authors: T. V. Beketova, N. F. Frolova, E. S. Stolyarevich, M. Yu. Volkov, O. N. Kotenko, E. N. Aleksandrova, Т. В. Бекетова, Н. Ф. Фролова, Е. С. Столяревич, М. Ю. Волков, О. Н. Котенко, Е. Н. Александрова

Source: Rheumatology Science and Practice; Vol 54, No 5 (2016); 543-552 ; Научно-практическая ревматология; Vol 54, No 5 (2016); 543-552 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20165

Subject Terms: гломерулонефрит, antineutrophil cytoplasmic antibodies, glomerulonephritis, антинейтрофильные цитоплазматические антитела

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2300/1504; Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1-11. doi:10.1002/art.37715; Vizjak A, Rott T, Koselj-Kajtna M, et al. Histologic and immunohistologic study and clinical presentation of ANCAassociated glomerulonephritis with correlation to ANCA antigen specificity. Am J Kidney Dis. 2003 Mar;41(3):539-49. doi:10.1053/ajkd.2003.50142; Pagnoux C, Carette S, Khalidi NA, et al. Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. Clin Exp Rheumatol. 2015;33(2 Suppl 89):S77-83.; Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003;41:776-84. doi:10.1016/S0272-6386(03)00025-8; Jennette JC, Thomas DB. Pauciimmune and cytoplasmic autoantibody-mediated crescentic glomerulonephritis and vasсulitis. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall’s Pathology of the Kidney. 6th ed. Philadelphia; 2007. P. 643-73.; Syed R, Rehman A, Valecha G, et al. Pauci-immune crescentic glomerulonephritis: an ANCA-associated vasculitis. Biomed Res Int. 2015;2015:402826. doi: 0.1155/2015/402826; Moroni G, Ponticelli C. Rapidly progressive crescentic glomerulonephritis: Early treatment is a must. Autoimmun Rev. 2014 Jul;13(7):723-9. doi:10.1016/j.autrev.2014.02.007; Rao JK, Weinberger M, Oddone EZ, et al. The role of antineutrophil cytoplasmic antibody Testing in the diagnosis of Wegener’s granulomatosis. Ann Int Med. 1995;123:925-32. doi:10.7326/0003-4819-123-12-199512150-00005; Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR project for ANCA assay standardization. Kidney Int. 1998;53:743-53. doi:10.1046/j.1523-1755.1998.00807.x; Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Investigat. 2002;110(7):955-63. doi:10.1172/jci200215918; Pfister H, Ollert M, Frö hlich LF, et al. Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood. 2004;104(5):1411-8. doi:10.1182/blood-2004-01-0267; Kallenberg CG. Pathogenesis of ANCA-associated vasculitides. Ann Rheum Dis. 2011 Mar;70 Suppl 1:i59-63. doi:10.1136/ard.2010.138024; Jha V. Renal and systemic vasculitis. In: Floege J, Johnson RJ, Feehally J, editors. Comprehensive Clinical Nephrology. St. Louis, MO: Saunders; 2010. P. 292-307.; Homeister JW, Jennette JC, Falk RJ. Immunologic mechanisms of vasculitis. In: Alpern RJ, Moe OW, Caplan M, editors. Seldinand Giebisch’s The Kidney. Amsterdam: Elsevier; 2013. P. 2817-46.; Eisenberger U, Fakhouri F, Vanhille P, et al. ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrol Dial Transplant. 2005;20:1392-9. doi:10.1093/ndt/gfh830; Seo P, Specks U, Keogh KA. Efficacy of rituximab in limited Wegener’s granulomatosis with refractory granulomatous manifestations. J Rheumatol. 2008 Oct;35(10):2017-23. Epub 2008 Aug 1. PubMed PMID: 18688911.; Holle JU, Hermann K, Gross, WL, et al. Comparative analysis of different commercial ELISA systems for detection of anti-neutrophil cytoplasm antibodies in ANCA-associated vasculitides. Clin Exp Rheumatol. 2012;30(70):66-9.; Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener’s granulomatosis. Am J Med. 2007;120:643.e9-643.e14. doi:10.1016/j.amjmed.2006.08.016; Davenport A. «False positive» perinuclear and cytoplasmic antineutrophil cytoplasmic antibody results leading to misdiagnosis of Wegener's granulomatosis and/or microscopic polyarteritis. Clin Nephrol. 1992;37:124-30.; Chen M, Kallenberg CG, Zhao MH. ANCA-negative pauciimmune crescentic glomerulonephritis. Nat Rev Nephrol. 2009 Jun;5(6):313-8. doi:10.1038/nrneph.2009.67; Wang F, Min Chen М, Zhao М-Н. Neutrophil degranulation in antineutrophil cytoplasmic antibodies-negative pauci-immune crescentic glomerulonephritis. J Nephrol. 2009.; Chen M, Yu F, Wang SX, et al. Antineutrophil cytoplasmic autoantibody-negative Pauci-immune crescentic glomerulonephritis. J Am Soc Nephrol. 2007 Feb;18(2):599-605. doi:10.1681/ASN.2006091021; Hung PH, Chiu YL, Lin WC, et al. Poor renal outcome of antineutrophil cytoplasmic antibody negative Pauci-immune glomerulonephritis in Taiwanese. J Formos Med Assoc. 2006;105:804e12.; Hedger N, Stevens J, Drey N, et al. Incidence and outcome of pauci-immune rapidly progressive glomerulonephritis in Wessex, UK: a 10-year retrospective study. Nephrol Dial Transplant. 2000 Oct;15(10):1593-9. doi:10.1093/ndt/15.10.1593; Shah S, Havill J, Rahman MH, Geetha D. A historical study of American patients with anti-neutrophil cytoplasmic antibody negative pauci-immune glomerulonephritis. Clin Rheumatol. 2016 Apr;35(4):953-60. doi:10.1007/s10067-015-3086-8; Sharma A, Nada R, Naidu GS, et al. Pauci-immune glomerulonephritis: does negativity of anti-neutrophilic cytoplasmic antibodies matters? Int J Rheum Dis. 2016 Jan;19(1):74-81. doi:10.1111/1756-185X.12729; Villacorta J, Diaz-Crespo F, Acevedo M, et al. Antineutrophil cytoplasmic antibody negative pauci-immune extracapillary glomerulonephritis. Nephrology (Carlton). 2016 Apr;21(4):301-7. doi:10.1111/nep.12608; Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. 1990;33:1101-7. doi:10.1002/art.1780330807; Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33:1094-100. doi:10.1002/art.1780330806; Pierrot-Deseilligny Despujol C, Pouchot J, Pagnoux C, et al. Predictors of a first Wegener’s granulomatosis relapse after obtaining complete remission. Rheumatology (Oxford). 2010;49(11):218190. doi:10.1093/rheumatology/keq244; Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66:222-7. doi:10.1136/ard.2006.054593; Luqmani R, Bacon P, Moots R, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87:671-8.; Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130:461-70. doi:10.7326/0003-4819-130-6-199903160-00002; Roth AJ, Ooi JD, Hess JJ, et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest. 2013;123:1773-83. doi:10.1172/JCI65292; Land J, Rutgers A, Kallenberg CG. Anti-neutrophil cytoplasmic autoantibody pathogenicity revisited: pathogenic versus non-pathogenic anti-neutrophil cytoplasmic autoantibody. Nephrol Dial Transplant. 2014;29:739-45. doi:10.1093/ndt/gft416; Csernok E, Moosig F. Current and emerging techniques for ANCA detection in vasculitis. Nat Rev Rheumatol. 2014;10:494-501. doi:10.1038/nrrheum.2014.78; Kallenberg CG. Key advances in the clinical approach to ANCAassociated vasculitis. Nat Rev Rheumatol. 2014 Aug;10(8):484-93. doi:10.1038/nrrheum.2014.104; Sampathkumar K, Ramakrishnan M, Sah AK, et al. ANCA negative pauci-immune glomerulonephritis with systemic involvement. Indian J Nephrol. 2010;20(1):43-7. doi:10.4103/0971-4065.62096; Shah S, Hruskova Z, Segelmark M, et al. Treatment of Severe Renal Disease in ANCA Positive and Negative Small Vessel Vasculitis with Rituximab. Am J Nephrol. 2015;41:296-301. doi:10.1159/000431336; De Lind van Wijngaarden RA, van Rijn L, Hagen EC, et al. Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis: the cause is hidden, but the result is known. J Clin Am Soc Nephrol. 2008;3:237-52. doi:10.2215/CJN.03550807; Corral-Gudino L, Borao-Cengotita-Bengoa M, Lerma-Marquez JL, del Pino-Montes J. Differences in the incidence of microscopic polyangiitis and granulomatosis with polyangiitis (Wegener’s). J Rheumatol. 2011;38:2494-6. doi:10.3899/jrheum.110650; Fujimoto S, Watts R, Kobayashi S, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibodyassociated vasculitis between Japan and the UK. Rheumatology. 2011;50:1916- 20. doi:10.1093/rheumatology/ker205; Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367(3):214-23. doi:10.1056/NEJMoa1108735; De Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, et al. Clinical and histologic determinants of renal outcome in ANCAassociated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol. 2006 Aug;17(8):2264- 74. doi:10.1681/ASN.2005080870; Lee SW, Yu MY, Baek SH, et al. Long-term prognosis of anti-neutrophil cytoplasmic antibody-negative renal vasculitis: Cohort study in Korea. J Korean Med Sci. 2016 Apr;31(4):542-6. doi:10.3346/jkms.2016.31.4.542; Munshi BD, Sengupta S, Sharan A, et al. Anti-neutrophil cytoplasmic antibody (ANCA)-negative small vessel vasculitis: A rare cause of pulmonary renal syndrome. Intern Med. 2015;54(21):2759-63. doi:10.2169/internalmedicine.54.4240; Baschinsky DY, Baker PB, Niemann TH, et al. Pauci-immune ANCA-positive crescentic glomerulonephritis associated with metastatic adenocarcinoma of the lung. Am J Kid Dis. 2000;36:E24. doi:10.1053/ajkd.2000.17727; Baldeo C, Ali R, Hritani A, et al. ANCA-negative pauci-immune crescentic glomerulonephritis linked with non-small cell carcinoma of the lung. Case Rep Nephrol Dial. 2015;5:168-72. doi:10.1159/000435808; Morikawa T, Yoshida A, Kobayashi S, et al. AP-VAS 2012 case report: a case of ANCA-negative pauci-immune crescentic glomerulonephritis associated with IL-6-producing adenosquamous cell carcinoma of the lung. CEN Case Rep. 2013;2:158-64. doi:10.1007/s13730-013-0058-1; Anaele CU, Srisung W, Tomacruz Y, et al. Antineutrophil cytoplasmic antibodies-negative pauci-immune crescentic glomerulonephritis associated with multiple myeloma. Case Rep Nephrol Dial. 2015 Jun 4;5(2):124-9. doi:10.1159/000432394; Wang J, Li L, Chen F, et al. Antineutrophil cytoplasmic antibody-negative pauci-immune crescentic glomerulonephritis and mantle-cell lymphoma: a case report and review of the literature. WIMJ Open. 2014;1(3):114. doi:10.7727/wimjopen.2014.198; Khan A, Lawson C, Quinn M, et al. Successful treatment of ANCA-negative Wegener's granulomatosis with rituximab. Int J Rheumatol. 2010, Article ID 846063, 2 pages. doi:10.1155/2010/846063; Shimizu M, Sekiguchi T, Kishi N, et al. A case of a 6-year-old girl with antineutrophil cytoplasmic autoantibody-negative pauciimmune crescentic glomerulonephritis. Clin Exp Nephrol. 2011;15:596-601. doi:10.1007/s10157-011-0423-3; Xing G, Chen M, Liu G, et al. Renal neutrophils infiltration in antineutrophil cytoplasmic antibodies-negative pauci-immune crescentic glomerulonephritis. Am J Med Sci. 2010;340(6):474-80. doi:10.1097/MAJ.0b013e3181f0768e; Cong M, Chen M, Zhang JJ, et al. Anti-endothelial cell antibodies in antineutrophil cytoplasmic antibodies negative pauciimmune crescentic glomerulonephritis. Nephrology. 2007;3:228-34.; Xing GQ, Chen M, Liu G, et al. Differential deposition of C4d and MBL in glomeruli of patients with ANCA-negative pauciimmune crescentic glomerulonephritis. J Clin Immunol. 2010; Jan;30(1):144-56. doi:10.1007/s10875-009-9344-2; Xiao H, Schreiber A, Heeringa P. Alternative complement pathway in the pathogenesis of disease mediated by antineutrophil cytoplasmic autoantibodies. Am J Pathol. 2007;170:52-64. doi:10.2353/ajpath.2007.060573; Huugen D, Esch AV, Xiao H, et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int. 2007;71:646-54. doi:10.1038/sj.ki.5002103; Schreiber A, Xiao H, Jennette JC, et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol. 2009;20:289-98. doi:10.1681/ASN.2008050497; Xing GQ, Chen M, Liu G, et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol. 2009;29:282-91. doi:10.1007/s10875-008-9268-2; Kain R, Matsui K, Exner M, et al. A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: The lysosomal membrane glycoprotein hLAMP-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells. J ExpMed. 1995;181:585-97. doi:10.1084/jem.181.2.585; Kain R, Exner M, Brandes R, et al. Molecular mimicry in pauciimmune focal necrotizing glomerulonephritis. NatMed. 2008;14:1088-96. doi:10.1038/nm.1874; Peschel A, Basu N, Benharkou A, et al. Autoantibodies to hLAMP-2 in ANCA-negative pauci-immune focal necrotizing GN. J Am Soc Nephrol. 2014 Mar;25(3):455-63. doi:10.1681/ASN.2013030320; Tang S, Zhang Y, Yin SW, et al. Neutrophil extracellular trap formation is associated with autophagy-related signalling in ANCAassociated vasculitis. Clin Exp Immunol. 2015;180(3):408-18. doi:10.1111/cei.12589; Kain R, Tadema H, McKinney EF, et al. High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis. J Am Soc Nephrol. 2012;23:556-66. doi:10.1681/ASN.2011090920; Roth AJ, Brown MC, Smith RN, et al. Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J Am Soc Nephrol. 2012;23:545-55. doi:10.1681/ASN.2011030273; Flint SM, Savage CO. Anti-LAMP-2 autoantibodies in ANCAassociated pauci-immune glomerulonephritis. J Am Soc Nephrol. 2012 Mar;23(3):378-80. doi:10.1681/ASN.2012010065

Availability: https://rsp.mediar-press.net/rsp/article/view/2300
https://doi.org/10.14412/1995-4484-2016-543-552

Granulomatosis with polyangiitis manifested with asthma-like syndrome followed by pneumonia6like syndrome ; Гранулематоз с полиангиитом: астмаподобное и псевдопневмоническое начало болезни

Authors: A. Yu. Tret'yakov, S. P. Zakharchenko, V. N. Shilenok, А. Ю. Третьяков, С. П. Захарченко, В. Н. Шиленок

Source: PULMONOLOGIYA; Том 25, № 6 (2015); 753-756 ; Пульмонология; Том 25, № 6 (2015); 753-756 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2015-25-6

Subject Terms: протеиназа3, ANCA, proteinase 3, антинейтрофильные цитоплазматические антитела

File Description: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/656/586; Мухин Н.А., ред. Интерстициальные болезни легких: Практическое руководство. М.: Литтерра; 2007.; Falk R.J., Jennette J.Ch. ANCA Disease: where is this field heading? J. Am. Soc. Nephrol. 2010; 21: 745–752.; Watts R.A., Mooney J., Skinner J. et al. The contrasting epidemiology of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis. Rheumatology. 2012; 51: 926–931.; Watts R.A., Scott D.G.I., Jayne D.R.W. et al. Renal vasculitis in Japan and the UK – are there differences in epidemiology and clinical phenotype? Nephrol. Dial. Transplant. 2008; 23 (12): 3928–3931.; de Campos F.P.F., Geller S.A. ChurgStrauss Syndrome: a syndrome described on clinical observation and autopsy findings. Autopsy Case Rep. 2013; 3 (2): 1–4.; Mercado U. Wegener's granulomatosis: the man behind the eponym. Cleve. Clin. J. Med. 1994; 61 (6): 428–430.; Woywodt A., Haubitz M., Haller H. et al. Wegener's granu lomatosis. Lancet. 2006; 367: 1362–1366.; Woywodt A., Matteson E.L. Wegener's granulomatosis – probing the untold past of the man behind the eponym. Rheumatology. 2006; 45 (10): 1303–1306.; Falk R.J., Cross W.L., Guilevin L. et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthrit. Rheum. 2011; 63 (4): 863–864.; Gross W.L. Mueller А., Holle J. The Granulomatosis of Wegener's. Delving deeper into the nonvasculitis aspects of the disease. The Rheumatologist. May 2011; www.therheumatologist.org; Pagnoux C., Stubbe M., Lifermann F. et al. Wegener's granulomatosis strictly and persistently localized to one organ is rare: assessment of 16 patients from the French Vasculitis Study Group database. Rheumatology. 2011; 38 (3): 475–478.; Holle J.U., Voigt C., Both M. et al. Orbital masses in gran ulomatosis with polyangiitis are associated with a refractory course and a high burden of local damage. Rheumatology. 2013; 52 (1): 262–269.; Кривошеев О.Г. Гранулематоз Вегенера и климат. www.vasculitis.ru; Baggiolini M., Bretz U., Dewald B. et al. The polymor phonuclear leukocyte. Agents Actions. 1978; 8 (1–2): 3–10.; Daum T.E., Specks U., Colby T.V. et al. Tracheobronchial involvement in Wegener's granulomatosis. Am. J. Respir. Crit. Care Med. 1995; 151 (2, Pt 1): 522–526.; Langford C.A., Sneller M.C., Hallahan C.W. et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener’s granulomatosis. Arthrit. Rheum. 1996; 39: 1754–1760.; Gluth М.В., Shinners P.A., Kasperbauer J.L. Subglottic stenosis associated with Wegener's granulomatosis. Laryngoscope. 2003; 113 (8): 1304–1307; https://journal.pulmonology.ru/pulm/article/view/656

Availability: https://journal.pulmonology.ru/pulm/article/view/656
https://doi.org/10.18093/0869-0189-2015-25-6-753-756

МЕЖДУНАРОДНЫЕ РЕКОМЕНДАЦИИ ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ ЭОЗИНОФИЛЬНОГО ГРАНУЛЕМАТОЗА С ПОЛИАНГИИТОМ - 2015

Authors: БЕКЕТОВА ТАТЬЯНА ВАЛЕНТИНОВНА, ВОЛКОВ М.Ю.

Subject Terms: СИСТЕМНЫЙ ВАСКУЛИТ,ЭОЗИНОФИЛЬНЫЙ ГРАНУЛЕМАТОЗ С ПОЛИАНГИИТОМ,АНТИНЕЙТРОФИЛЬНЫЕ ЦИТОПЛАЗМАТИЧЕСКИЕ АНТИТЕЛА,SYSTEMIC VASCULITIS,EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS,ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES

File Description: text/html

Availability: http://cyberleninka.ru/article/n/mezhdunarodnye-rekomendatsii-po-diagnostike-i-lecheniyu-eozinofilnogo-granulematoza-s-poliangiitom-2015
http://cyberleninka.ru/article_covers/17022514.png

Трудности диагностики гранулематоза Вегенера у взрослых в современной клинической практике (клиническое наблюдение)

Authors: БАБАЕВА А.Р., КАЛИНИНА Е.В., ЗВОНОРЕНКО М.С.

Subject Terms: ГРАНУЛЕМАТОЗ ВЕГЕНЕРА,АНТИНЕЙТРОФИЛЬНЫЕ ЦИТОПЛАЗМАТИЧЕСКИЕ АНТИТЕЛА (АНЦА),WEGENER''S GRANULOMATOSIS,ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES

File Description: text/html

Availability: http://cyberleninka.ru/article/n/trudnosti-diagnostiki-granulematoza-vegenera-u-vzroslyh-v-sovremennoy-klinicheskoy-praktike-klinicheskoe-nablyudenie
http://cyberleninka.ru/article_covers/16914498.png